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ABSTRACT 
Evaluation of Endothelial Cell Responses to Elevated Glucose In Vitro 
Gabriella Paige Byrd Sugerman 
 Developing a tissue-engineered Blood Vessel Mimic (BVM) to represent diabetic 
macrovascular disease could expedite design of new vascular devices specifically tailored to 
diabetic patients. In contribution toward this model, this thesis assessed Human Umbilical Vein 
Endothelial Cell (HUVEC) responses to high glucose conditions. Interleukin 6 (IL-6) and Cluster 
of Differentiation 36 (CD36) were selected to signify oxidative stress activity, a hallmark of 
diabetic macrovascular disease. Next, activity of potential reference genes B2M, HPRT1, and 
ACTB was assessed. All genes were found to exceed acceptable variability, so the E-ΔCT method 
of data analysis was selected. Next, cellular responses to high glucose treatment at 10.5 mM 
glucose and 25.5 mM glucose for 7 and 14 days were measured by qPCR. IL-6 mRNA 
expression increased significantly (p<0.001) following treatment with 25.5 mM glucose at both 
timepoints.  
Finally, fluorescent staining for Reactive Oxygen Species (ROS) production and cell 
viability was performed on HUVECs treated with 10.5- and 25.5-mM glucose for 24 and 48 
hours. No differences in ROS production or cell viability were detected due to uncontrolled cell 
damage during the two-hour staining and imaging procedure. This thesis was limited by low 
reaction efficiency in qPCR reactions due to mistaken purchasing of primers with included 
probe-quencher reporters. Measurement of reaction efficiency facilitated valid analysis of data 
collected using these primers. Imaging experiments were unsuccessful due to a lack of 
incubation equipment designated for cells undergoing live staining and imaging. Alternative 
imaging assessments of oxidative stress activity were proposed to circumvent this problem.   
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1.  INTRODUCTION 
1.1 Diabetes Mellitus 
1.1.1 Prevalence 
 Diabetes is extremely prevalent in the United States, and incidence is on the rise. The 
Centers for Disease Control release an annual National Diabetes Statistics Report and estimate 
that in 2015, 9.4% of the U.S. population—over 30 million people—had diabetes [1]. Of those, 
95% had Type 2 Diabetes, which is primarily caused by lifestyle factors [1]. Insulin resistance 
and associated endothelial dysfunction often begin many years before diagnosis of Type 2 
Diabetes and is increasing among normoglycemic individuals, with estimates of insulin 
resistance reaching 32.2% in 1999-2002 [2]. 
1.1.2 Pathology 
 Diabetes Mellitus is a metabolic disease wherein glucose is improperly processed by the 
body, potentially leading to widespread tissue damage. There are two distinct pathologies that 
differ according to which mechanism of insulin-mediated glucose uptake that is dysfunctional. 
Type 1 Diabetes is characterized by autoimmune destruction of insulin-producing pancreatic β 
cells, leading to negligible blood insulin concentrations. Type 2 Diabetes is characterized by 
resistance to insulin signaling, leading to an elevated blood insulin concentration [3]. Though the 
two diseases share many symptoms, including endothelial dysfunction and macrovascular 
disease, this thesis focuses on the more common and preventable Type 2 Diabetes [1]. 
In normoglycemic patients, cellular glucose uptake occurs through two balanced 
mechanisms. Insulin-mediated glucose transport occurs through the cell membrane protein 
GLUT4 on adipose and muscle cells and non-insulin-mediated glucose transport occurs on all 
cells through GLUT1. When insulin resistance develops, transport using GLUT4 decreases and 
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the mass balance effect leads to increased GLUT1 utilization. One byproduct of glucose 
metabolism through GLUT1 is hexosamine, which has a negative feedback effect on GLUT4 and 
exacerbates development of insulin resistance [4]. Decreased insulin utilization leads to 
hyperinsulinemia, a hallmark of Type 2 Diabetes which is absent in Type 1 Diabetes.  
When a molecule of glucose enters a cell, it undergoes glycolysis initiated by hexokinase 
in the cytosol and is converted to two three-carbon molecules of pyruvate. Pyruvate is 
transported to the mitochondria where the citric acid cycle, also known as the Kreb’s Cycle, 
converts it to acetyl-CoA. This cycle yields energy in the form of adenosine triphosphate (ATP) 
and byproducts NADH and FADH2, which initiate the electron transport chain along the 
mitochondrial membrane. The electron transport chain converts high-energy NADH and FADH2 
molecules to additional ATP [5]. In Type 2 Diabetes, excess glucose flux causes insufficient 
hexokinase enzyme availability and additional glucose enters the polyol pathway, leading to 
increased sorbitol production, which induces oxidative stress. Additionally, NADPH is depleted, 
producing an increased NADH/NAD+ ratio which further contributes to oxidative stress [6].  
Oxidative stress caused by hyperglycemia can cause several coincident conditions in 
multiple organ systems. An increased amount of circulating glucose is widely understood to 
trigger mitochondrial production of reactive oxygen species (ROS). These oxygen-containing 
molecules include radical electrons, allowing them to bind essential molecules like DNA and 
proteins, thereby worsening oxidative stress conditions in the cells [7]. This activates a 
continuous inflammatory response, leading to systemic damage over long periods of time, 
including degradation of the nervous and circulatory systems [8].  
Figure 1.1 summarizes how symptoms progress as insulin resistance increases, and how 
hyperinsulinemia progresses in diagnosis to Type 2 Diabetes [8]. Circulating glucose also causes 
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cellular damage by creating advanced glycation end products (AGEs), protein and lipid 
molecules modified by exposure to glucose [9]. AGEs are influential cellular signals, initiating 
vascular constriction and vascular stiffening that results in systemic atherosclerosis [10]. In Type 
2 Diabetes, vascular stiffening manifests in the entire body from retinopathy to peripheral 
neuropathy, but the highest mortality rate is caused directly by cardiac macrovascular disease 
[1].  
 
Figure 1.1: Insulin Resistance Increases with Disease State. Progression of severity of insulin 
resistance and the associated diagnoses with their associated macrovascular symptoms [5]. 
Macrovascular disease evolves slowly over an individual’s lifetime. As chronic stiffening 
and occlusion of blood vessels, or atherosclerosis, progresses over time, symptoms penetrate 
from the innermost to outermost layers of blood vessels. The innermost lining of blood vessels is 
composed of endothelial cells (ECs), which undergo glucose-sensitive signaling pathways in 
response to oxidative stress. In healthy endothelial cells, insulin signaling leads to 
phosphorylation of endothelial nitric oxide synthase (eNOS), which increases nitric oxide 
production [11]. This process becomes dysfunctional as insulin resistance develops, with 
significant downregulation of insulin receptor substrate 1 (Irs1) and eNOS [12]. In a mouse 
model using overexpression of a dominant negative endothelium-specific insulin receptor 
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(ESMIRO), endothelial insulin resistance has been shown to decrease vasorelaxation responses 
to acetylcholine, increase superoxide production, and promote development of atherosclerotic 
lesions [11, 13]. Endothelial cells transmit insulin from the bloodstream to skeletal muscle, a 
primary location for insulin-mediated glucose metabolism, so when endothelial insulin signaling 
is disrupted, glucose uptake by skeletal muscles is decreased [12] and hyperglycemia is 
aggravated.  
These pathways promote inflammation and, in combination with AGE signaling, create a 
pro-atherosclerotic environment within vessels [3, 8]. Atherosclerosis is traditionally treated with 
angioplasty or stenting, procedures intended to increase the inner diameter of the blood vessel by 
compressing plaques [14]. Due to chronic pro-inflammatory conditions present in diabetes, 
historically these procedures have a lower rate of success in diabetic patients than in non-diabetic 
conditions [4, 10–13]. Figure 1.2 depicts the increase in adverse outcomes like death, cardiac 
events, and repeat procedures among diabetic patients [17]. 
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Figure 1.2: Decreased Event-Free Survival in Diabetic Patients with Vascular Stents [13]. 
Adverse events include death, cardiopulmonary events (stroke, myocardial infarction, pulmonary 
embolism) and restenosis. 
Every improvement to current practice has closed the gap between diabetic and non-
diabetic populations [19], but it persists, and has driven medical device companies to design 
stents and other vascular interventions specifically for diabetic patients [15, 16].  
1.2 Traditional Device Testing Progression 
 To ensure patient safety, newly designed medical devices must be thoroughly tested 
before clinical trials take place. Traditionally, testing applicability of newly designed devices for 
diabetic patients requires development of diabetic animal models. A perfect animal model for 
atherosclerosis and vascular stenting in Type 2 Diabetes is elusive. The many attempts to 
develop such a model attest to this challenge. Canine models were used historically, with stents 
deployed in coronary and peripheral arteries. However, canine arteries have noticeably different 
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coagulation and intimal healing patterns than human counterparts, and results from canine trials 
failed to predict success of human trials [22].  
Artificially-induced atherosclerosis often produces endothelial abrasions on otherwise 
healthy rats, rabbits, and swine [23], leading to a very different habitat for recovery than a 
diabetic blood vessel. Drug-induced diabetic animal models and 2D cell-culture models are used 
in tandem to evaluate stent quality [15], but cannot predict the outcome of clinical testing [17–
20]. Tissue engineering, a broad term for combining engineered materials and living cells to 
create functional constructed tissues, has enabled device designers to conduct intermediate 
research between established 2D benchtop testing methods and costly animal trials [26].  
1.3 Blood Vessel Mimics 
 In order to test vascular devices, Cal Poly’s Tissue Engineering Lab cultivates tissue-
engineered blood vessel mimics (BVMs) using polymer scaffolds and human vascular cells. 
Cells are derived from umbilical cord veins isolated and pooled over multiple donated umbilical 
cords. Cells from the innermost layer are referred to as Human Umbilical Vein Endothelial Cells 
(HUVECs). HUVECs are cultured before being harvested and injected into a polymer scaffold.  
Scaffolds are fabricated by electrospinning, wherein thin fibers of poly-lactic-co-glycolic-
acid (PLGA) are pulled by electrostatic attraction to form a thin tube around a translating and 
rotating mandrel. The scaffold is conditioned in high-protein media to promote cell adhesion 
before cells are sodded under high pressure to promote penetration into the walls of the scaffold.  
The scaffold takes the role of the tunica adventitia, the outermost fibrous layer of a blood vessel. 
In some cases, human smooth muscle cells isolated from the umbilical artery (HUASMCs) are 
sodded first, creating a muscular tunica media, before human endothelial cells isolated from the 
umbilical vein (HUVECs) are sodded to create a tunica intima [27]. Figure 1.3 compares blood 
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vessel layers to corresponding components of the BVM. To isolate the endothelial dysfunction 
response to elevated glucose, models in this thesis contain only HUVECs. Over time, the cells 
form a robust layer, which can respond to environmental conditions like high glucose 
concentration or foreign objects like implanted stents.  
 
Scaffolds are incorporated into a bioreactor, a closed system whereby cell media can be 
pumped through vessel mimics under pulsatile flow. Figure 1.4 depicts the path of cell media 
through the peristaltic pump, bioreactor, and cell media reservoir.  
Figure 1.3: Blood Vessel and BVM Layers. Blood vessels are composed of tunicae intima, media, 
and adventitia, while BVMs are composed of polymer scaffolds and cell linings. 
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1.3.1 Inducing Elevated Glucose Conditions in BVMs 
 To replicate the hyperglycemic conditions present during prediabetes and Type 2 
Diabetes, additional glucose can be added to cell media [28]. Standard cell media contains 5.5 
mM glucose as a source of cellular energy, meant to reproduce the concentration of glucose in 
the blood in a normoglycemic individual. To imitate prediabetic conditions, glucose 
concentration can be increased to 10.5 mM; to imitate diabetic conditions, the concentration can 
be 25.5 mM (Table 1.1). Moderate glucose media was made by combining 8.40 mL 80 mM 
sterile glucose solution with 116.6 mL cell media, and high glucose media was made by 
combining 33.55 mL 80 mM glucose with 91.45 mL cell media. These concentrations have been 
previously established as sufficient to influence cell behavior as measured by changes in gene 
expression [28]. The glucose concentration required to detect changes in viability representative 
of diabetic conditions is higher in cultured cells compared to recently-isolated primary cells. This 
difference is related to changes in glucose utilization of proliferating cells in culture [29, 30].  
Figure 1.4: Bioreactor Schematic in the Cal Poly Tissue Engineering lab. Cells are sodded into 
polymer scaffold before incorporation into peristaltic flow system. Cell media is pushed through 
tubing, through the lumen of the BVM, circulating as cell layer develops. Stopcocks isolate flow 
through transmural or transluminal paths. 
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Table 1.1: Elevated Glucose Conditions 
Treatment 
Label 
Total Glucose 
Concentration 
(mM) 
Total Glucose 
Concentration 
(mg/dL) 
Represented Disease State [22] 
(Diagnostic Fasting Plasma 
Glucose) 
Basal  5.5 99 Normoglycemic  
(<100 mg/dL) 
Moderate  10.5 189 Prediabetic 
(100-125 mg/dL) 
High  25.5 459 Diabetic 
(>126 mg/dL) 
 
 Exposing BVMs to high glucose conditions is the first step toward potentially 
approximating the environment of a diabetic blood vessel. If the conditions are sufficiently 
similar, the BVMs should exhibit oxidative stress, a well-documented cellular response to 
elevated glucose [9, 24, 25].  
1.4 Cellular Responses and Expression of mRNA and Proteins 
1.4.1 Cellular Response to Oxidative Stress and qPCR 
Glucose molecules signal mitochondria to increase production of ROS, which bind and 
inactivate a wide range of molecules within the cell. This process in turn further increases ROS 
production through a positive autoregulatory feedback loop. An imbalance of ROS and ROS-
quenching molecules, or antioxidants, leads to a condition known as oxidative stress. Oxidative 
stress can be useful to the body, signaling immune responses to foreign antigens. In chronic 
oxidative stress conditions, however, it leads to endothelial dysfunction, the precursor to 
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macrovascular damage characteristic of diabetes. This occurs when stress-sensitive pathways are 
activated, notably the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
pathway. ROS and inflammatory cytokine interleukin-6 (IL-6) bind their extracellular receptors, 
initiating a signaling cascade which activates NF-κB. When activated, NF-κB translocates into 
the nucleus and acts as a transcription factor for inflammatory cytokines like IL-6 and CD36 and 
sorbitol, which in turn increases ROS generation and produces AGEs. Figure 3 depicts NF-κB 
and connected pathways, including mitogen-activated protein kinase (MAPK) and Janus 
kinase/signal transducers and activator of transcription (JAK/STAT) pathways. These increase 
insulin resistance and Beta cell dysfunction, the systemic metabolic implications of diabetes. 
They also trigger endothelial dysfunction in the forms of chronic vasoconstriction, arterial 
stiffening, and development of atherosclerosis [33]. 
 
Figure 1.5: Pathways Involved in Hyperglycemia-Induced Endothelial Damage. Many pathways 
interact to initiate diabetic macrovascular disease. Both targets for gene expression analysis are 
mechanistically understood to be upregulated under hyperglycemic conditions [8]. 
 Interleukin 6 (IL-6) is both an inflammatory chemokine which initiates the appropriately 
named “signal transducer and activator of transcription” (JNK/STAT) pathway and a product of 
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the same pathway. This gives IL-6 both autocrine feedback to the same cell, upregulating soluble 
IL-6 production and further increasing mRNA abundance therein [34], and paracrine feedback to 
nearby cells, which creates signal amplification in localized tissues. Increased IL-6 activity with 
increased extracellular glucose concentration therefore could represent one step toward a 
successful model of diabetic macrovascular disease.  
 Cluster of Differentiation 36 (CD36) is a cell surface scavenger receptor and has been 
shown to increase production of ROS and smooth muscle cell endocytosis of oxidized LDL, a 
building block of atherosclerotic plaques [35]. Mechanistically, CD36 binds its receptor and 
triggers the PPAR-γ pathway [36]. This pathway boosts production of CD36 and fatty streak 
accumulation in vivo. Increasing CD36 expression correlated with elevated glucose 
concentration is therefore another potential accomplishment in designing a BVM with diabetic 
vascular disease [31]. After identifying the key pathways promoted by a high glucose 
environment, determining a means of measurement would be necessary to reveal how closely 
BVMs in these conditions replicate human blood vessels undergoing disease processes. 
1.4.1.1 Reverse-Transcription Quantitative Polymerase Chain Reaction (RT-qPCR) 
Cellular response to high-glucose conditions can be assessed using reverse-transcription 
quantitative polymerase chain reaction (RT-qPCR). Polymerase chain reactions (PCR) amplify 
the amount of a target sequence of DNA which can be used for further study. PCR utilizes the 
enzyme DNA Polymerase, which covalently bonds corresponding Watson-Crick base pairs with 
the template DNA strand. DNA templates here are from the treated cells, and additional free 
nucleotides are added to the solution. The solution is heated, or denatured, to break hydrogen 
bonds between the two strands of DNA, exposing unpaired nucleotides to be copied. DNA 
Polymerase cannot bind to the template strand without a complementary nucleotide primer in 
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place on the template strand, which creates a small double-stranded section. This allows for 
extremely targeted replication of a specific DNA fragment. Under engineered conditions, DNA 
Polymerase replicates the DNA exponentially over repeated cycles of denaturation, annealing, 
and extension.  
Quantitative PCR (qPCR) uses the same enzymes and principles as traditional PCR but 
adds a fluorescent reporter molecule, which emits light proportionally to the number of double-
stranded DNA molecules present during any given cycle of PCR. qPCR instruments analyze and 
report fluorescence during each successive cycle, and due to the programmable temporal scale of 
PCR, allow for back-calculation of starting copy number for each sample. Exponential 
amplification of target sequences allows for differentiation between relatively similar starting 
copy numbers, offering accurate measurements of relative abundance of specific gene sequences 
between samples.  
Reverse transcription (RT) is an enzymatic reaction which uses Reverse Transcriptase to 
transcribe complementary DNA (cDNA) from RNA. Within a cell, RNA transmits 
communication between the nucleus and the organelles responsible for modifying cell behavior. 
Messenger RNA (mRNA) in particular relays information by acting as the template in the 
process of encoding proteins. When extracellular signals initiate cascades that evolved in 
response to stress, transcription factors bind nuclear DNA in specific places, increasing the 
number of copies of those particular mRNAs in order to increase production of the associated 
protein. This process is how cells respond to their environments, making mRNA abundance an 
appropriate indicator of the activation of stress-response pathways.  
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1.4.1.2 Genes of Interest 
Due to the granularity of the differences in relative mRNA abundance elucidated by RT-
qPCR across treatment groups, genes must be selected to accurately represent changes in cell 
behavior. The genes CD36 and IL-6, the functions of which are described in detail above, were 
chosen for study through RT-qPCR in the hopes of capturing the acute endothelial cell response 
to increased extracellular glucose.  
1.4.1.3 Reference Genes 
 To accurately compare levels of mRNA expression across various samples, 
concentrations of nucleic acid must be identical. This is approximated as closely as possible by 
measuring RNA concentration before reverse transcription to cDNA, but to further control for 
variability, samples are also assessed for mRNA abundance of genes which should not be 
affected by increasing extracellular glucose. Three reference genes are evaluated in this thesis.   
Beta-actin (ACTB)  
 ACTB encodes for one of two cytoskeletal actin proteins [37].  All human cells express 
ACTB similarly and cytoskeletal function is not known to be affected by extracellular glucose, 
making ACTB a suitable reference gene with which to normalize qPCR results.  
Beta-2 microglobulin (B2M) 
 B2M encodes for a component of the Major Histocompatibility Complex 1 (MHC Class 
1), which allows cells to display non-self-proteins to cytotoxic T cells [38]. This is an important 
function of immunity, and MHC class 1 is found on all nucleated human cells (excluding red 
blood cells). 
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Hypoxanthine-guanine phosphoribosyltransferase (HPRT1) 
 HPRT1 encodes for protein HGPRT which is a catalytic enzyme involved in synthesizing 
purine nucleotides, adenine and guanine [39]. Nucleotides are required for translation and 
transcription of genetic material, making HPRT1 essential to all human cells.  
1.4.2 Reactive Oxygen Species and Fluorescent Microscopy 
 To complement qPCR-based gene expression analysis, fluorescent staining for cell 
viability and ROS expression can be analyzed across glucose treatment groups. Cell viability 
gives a general estimation of how well cells are surviving and replicating [40]. Extracellular 
glucose interferes with cell survival by upregulating mitochondrial production of ROS, signaling 
apoptosis via the transcription factor Sp1 [27, 28]. Cell death due to hyperglycemia is a major 
component of endothelial dysfunction and the pathology of diabetic macrovascular disease [43] 
so visualizing and quantifying cell viability offers insight into progression of high glucose-
induced oxidative stress pathways. Decreasing cell viability by approximately 12% with 
increasing glucose concentrations contributes to a physiologically relevant model [27, 30].  
1.5 Summary and Aims of this Thesis  
 In progression toward a tissue engineered blood vessel mimic system suitable for testing 
devices intended to treat diabetic macrovascular disease, this thesis pursued the following 
specific aims:  
Aim 1: To identify genetic corollaries that indicate increased oxidative stress responses 
in endothelial cells, and to determine a method by which to study specific corollaries in gene 
expression. 
Evaluation of oxidative stress response pathway activity by RT-qPCR requires selection 
of genes whose change in regulation will represent pathway activation. Chapter 2 details this 
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selection process. Data analysis methods for RT-qPCR make use of reference genes that remain 
constant across treatment groups. Determination of the suitability of those reference genes as 
well as comparisons between mRNA expression of genes of interest depends heavily on the 
methodology used for data analysis. Principles of and popular approaches to data analysis are 
also discussed in Chapter 2.  
Aim 2: To evaluate endothelial cell expression over time for the markers CD36 and IL-
6 in titered glycemic conditions representative of healthy, prediabetic, and diabetic individuals.  
Based on data analysis protocols and genes of interest determined in Chapter 2, an 
examination of gene expression in Human Umbilical Vein Endothelial Cells (HUVECs) treated 
with extracellular glucose concentrations representative of diabetic progression over seven and 
fourteen-day timepoints was conducted. Results of these experiments are presented and 
discussed in Chapter 3.  
Aim 3: To assess effect of elevated glucose over time on in vitro endothelial cell 
viability and reactive oxygen species (ROS) production at titered glucose concentrations 
representative of healthy, prediabetic, and diabetic conditions. 
 Cell viability and ROS product were measured using a combination of fluorescent stains 
and confocal microscopy techniques. Fluorescent staining permits image-based analysis of cell 
viability and function by differentiating live and dead cells and by fluorescing proportionally to 
the amount of cell products generated. Imaging-based analysis is particularly relevant to the 
BVM system because these stains can be used to evaluate blood vessel mimics as a whole. 
Staining, imaging, and image processing are described in detail in Chapter 4.  
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2 DETERMINING GENES OF INTEREST AND OPTIMIZING QPCR DATA 
ANALYSIS 
2.1: Introduction 
 Tissue engineered models are inherently imperfect; it is impossible to capture a complex 
disease process in a model disconnected from a living organism. Measuring this inaccuracy 
proves to be a difficult task in itself, as there are dozens of cell types with hundreds of genes with 
known involvement in development of atherosclerosis and diabetic macrovascular disease [45]. 
Gene expression analysis is a powerful tool for evaluating cellular responses, granted that the 
genes analyzed accurately represent those responses, and that data is analyzed properly. Gene 
selection involves reviewing literature to identify prominent pathways and choosing targets that 
have established response patterns in vivo in diabetic patients. Data analysis depends on thorough 
experimental controls and appropriate comparisons, as spurious conclusions can emerge when 
data is mishandled. This chapter describes preliminary decisions and experiments necessary to 
compare the elevated glucose BVM model to the diabetic macrovascular disease state.  
2.2: Gene Selection and Primer Acquisition  
 A process as complex as the development of diabetic macrovascular disease involves 
dozens of individual genes coordinating responses to varying stimuli [35]. Known oxidative 
stress pathways involve multiple points of origin and dozens of potential genetic targets of 
analysis.  
Genes investigated to represent diabetic macrovascular disease were CD36, CD68, 
COX2, iNOS, IL-1A, IL-6, PLA2G7, and PPARγ. Proinflammatory cytokines CD36, CD68, IL-
1A, and IL-6 are upregulated in Type 2 Diabetes and initiate a positive feedback loop by which 
acute inflammation becomes uncontrolled [24, 35–37]. Uninhibited inflammation contributes to 
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endothelial dysfunction present in diabetic macrovascular disease [7]. PLA2G7 or phospholipase 
A2 converts circulating phospholipids to arachidonic acid which is cleaved by COX2 or cyclo-
oxygenase-2 into prostaglandin H2 [38–40]. The presence of COX2 rather than COX1, a 
functionally similar molecule, is correlated with hyperglycemia-induced inflammation [50]. 
Inducible nitric oxide synthase (iNOS) gene variants are associated with poorer clinical 
outcomes in Type 2 diabetic patients [52] and animal models correlate increased iNOS 
expression with endothelial dysfunction [53]. Finally, PPARγ is a master regulator of fatty acid 
uptake and is implicated in development of atherosclerosis [54]. Genes that were considered as 
experimental targets for this thesis are summarized in Table 2.1.  
Table 2.1: Initial Genes of Interest  
Gene† Function Pathway Ref. 
CD36 Binds oxLDL and AGE-modified proteins PPARγ [31] 
CD68 Correlated with insulin sensitivity and IL-6 secretion NFκB [46] 
COX2 Proinflammatory, associated with Type 2 Diabetes AA‡  [50] 
iNOS Oxidative stress, NO production MAPK [53] 
IL-1A Inflammatory cytokine  NFκB, MAPK [47] 
IL-6 Immunoregulation, glucose metabolism JNK/STAT [48] 
PLA2G7 Promotes oxLDL formation, plaque instability AA/MAPK [49] 
PPARγ Glucose metabolism, fatty acid uptake, master regulator PPARγ [55] 
†HGNC official gene names ‡ Arachidonic acid pathway 
Once these 8 primary genes of interest were identified, the next step was to acquire PCR 
reagents to evaluate their utility.  This took place in three steps: initial primer design, preliminary 
verification of custom primers, and a decision to use preverified primers. Primer sequences for 
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all 8 genes and purchasing information for all qPCR analyses are provided in Appendix A and 
will be described below. 
2.2.1: Initial Primer Design 
Multiple primer sequences were designed and tested for each of the eight preliminary 
gene targets. Sequences were acquired from the NCBI gene sequence database GenBank and 
primers were designed using the IDT PrimerQuest tool (idtdna.com/primerquest) and the NCBI 
Primer BLAST tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast).  
To summarize the process, sequences were searched for in the GenBank Homo sapiens 
mRNA database by HGNC name. Sequences were then entered into PrimerQuest and custom 
design parameters were chosen. Primer size was limited to 18-22 nucleotides to encourage 
binding only onto genes of interest. Primer melting temperature, Tm, was limited to 59-61°C to 
facilitate evaluation of multiple primer sets using the same qPCR settings. Amplicon size was 
limited to 180-220 bp to equalize annealing times across PCR products and also facilitate 
evaluation of multiple genes using the same qPCR settings. PrimerQuest then generated five 
ranked potential primer sets which were copied to Primer BLAST to check for homology with 
non-target genes. Primer BLAST tested inputted sequences against all consensus mRNA 
sequences and primers were deemed acceptable when only target genes were returned. This step 
ensured only the gene of interest was amplified. Once the primers were confirmed to have no 
homologs, the highest-ranked primer sets were selected and ordered from the PrimerQuest tool. 
A detailed protocol for primer design, ordering, and selection can be found in Appendix B. 
Figure 2.2 shows Delta Rn vs Cycle Number for one or two custom primer sets for each 
of the eight preliminary genes of interest, totaling 14 sets. Delta Rn is the derivative of 
fluorescence intensity and Cycle Number represents qPCR progression. Many of these primers 
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failed to amplify, demonstrated by lines that never crossed the horizontal threshold line through 
the linear amplification region (“B”). Some reactions, including one shown in light green in 
Figure 2.1 (“A”), had irregular amplification patterns that suggest the formation of unwanted 
PCR products. 
  
Irregular replication and lack of replication in many wells demonstrated the faults of 
these primers. Many amplification curves intersected, implying unequal reaction efficiency 
across wells.  
Figure 2.1: Amplification Plot of All Initial Primers. Each line represents one individual qPCR 
sample. The x-axis represents cycle number, or progress of the qPCR, while Delta Rn on the y-
axis represents change in fluorescence intensity. The Delta Rn value is the derivative of 
fluorescence intensity. Sample A shows irregular replication while Samples in Region B failed to 
replicate.  
 
A 
B 
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2.2.2 Methods: qPCR and Visual Analysis for Primer Quality 
As described briefly in Chapter 1, qPCR measures relative expression of genes across 
samples by repeatedly separating and replicating target strands. Primers obtained for each gene 
(Appendix A), template cDNA, DNA polymerase, unpaired nucleotides (dNTPs), and enhancers 
were combined for each reaction into well plates. Well plates were placed in a thermocycler with 
qPCR functionality. To begin qPCR, samples were heated to 95° C to denature, or separate, 
strands of DNA. Samples were then cooled to 60°C to allow primers to bind to their 
complementary sequences, at which point DNA polymerase extended to replicate the template 
strand. Intercalating dye molecules fit between base pairs of DNA as strands anneal and extend, 
with the amount of intercalated dye being proportional to the amount of DNA present. The 
thermocycler then measured fluorescence of intercalating dye, marking the completion of one 
cycle of the reaction. Following completion of forty cycles, a dissociation step tracked 
fluorescence as temperature gradually increased. Temperature at which PCR products dissociate 
is determined by identity, so all products which dissociated at approximately the same 
temperature were assumed to be equivalent. A complete protocol for preparing and running 
qPCR is available in Appendix C. 
During qPCR, measured fluorescence in each well was reported by the thermocycler 
during each reaction cycle. Amplification curves were generated from these measurements and 
facilitate comparison of reactions. As cycles progressed, fluorescence increased linearly before 
reaching a plateau as available nucleotides were depleted. In order to compare relative 
abundance, a common threshold was established for all samples by drawing a line across the 
linear region of all amplification curves on the plate. The cycle at which each sample reached the 
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threshold is known as the CT, or “cycles to threshold,” value. The CT value of each sample is the 
basis for comparing relative abundance. Figure 2.2 depicts an amplification plot and labels its 
linear region, threshold, and CT value.  
Primers were tested by RT-qPCR with cDNA derived from Human Umbilical Vein 
Endothelial Cells (HUVECs) (Lonza, C2519A) at passage 5 cultured in corresponding cell 
culture media (Lonza, EGM Plus) to 80% confluence in T-75’s and passaged at 1:3 ratios 
throughout culture. RNA isolation and cDNA synthesis were performed before qPCR and 
generation of corresponding amplification plots. Amplification curves for each set of primers 
were evaluated visually for similarity of amplification across replicates. Amplification curves 
which intersected in the linear region demonstrated unequal reaction efficiencies and were 
rejected. Amplification curves which lacked the expected biconcave shape were also rejected, 
including those which never crossed the threshold line.  
Figure 2.2: Amplification Plot with Linear Amplification Region, 
Threshold, and CT. 
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2.2.3 Preliminary Primer Verification 
During primer selection, primers that failed visual evaluation were rejected. The five sets 
of custom primers that successfully replicated are presented in Figure 2.3 as a demonstration of 
primer selection. Genes represented are CD68, IL-1A, PPARγ, and PTGS2 (two successful sets). 
CD36 and IL-6 primer sets failed to replicate. 
 
 
This was only the first validation step required to reliably make conclusions from custom 
primers, as variability of replication efficiency is evident in Figure 2.3 where amplification 
curves intersect. A complete protocol for primer selection is available in Appendix B.  
Figure 2.3: Amplification Plots of Successful Initial Primers. Isolated here are only those 
primers which produced three CT values approximately equal to one another. As in Figure 2.2, 
the x-axis represents PCR progression and the y-axis represents change in fluorescence 
intensity. Each line represents one sample qPCR well.  
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2.2.4 Preverified Primers 
Although the primers in Figure 2.3 were appropriate for further validation, they were not 
ultimately used in this thesis. Failure to replicate CD36 and IL-6 genes was especially 
problematic as these genes are particularly well-studied compared to other genes of interest.  
Owing to the recurring associations of CD36 and Il-6 with diabetes and endothelial dysfunction, 
these two gene targets were necessary to consider given the aims of this thesis. CD36 mRNA 
expression was previously documented to increase in response to elevated glucose 
concentrations in microvascular endothelial cells and this upregulation was demonstrated to 
mediate oxidative stress [31]. In a genome-wide study, CD36 variants were associated with 
changes in lipoprotein diameter in response to fenofibrate, an insulin resistance treatment, 
indicating CD36 may be related to insulin resistance through lipoprotein pathways associated 
with atherosclerosis [56]. A CD36 knockout mouse model (mice without the gene for CD36) 
demonstrated decreased inflammation and increased insulin signaling compared to wild-type 
mice [57]. Plasma IL-6 concentration and advanced glycation end products were both shown to 
have increased in diabetic patients compared to non-diabetics [58] and IL-6 was recently shown 
to be involved with procoagulant molecule thrombin in the transition from acute to chronic 
inflammation [34]. Acquiring primers to evaluate expression of CD36 and IL-6 required 
repetition of custom primer design or pursuit of another solution.  
Due to the cost of repeating attempts at primer design and verification, and in an effort to 
streamline data acquisition, pre-verified primers were purchased for CD36 and IL-6. The 
increased cost of these primers (approximately $130 for one preverified set compared to $15 for 
one set of custom primers) necessitated a reduction in the number of experimental targets, so 
other genes of interest were not investigated further in this thesis. PrimeTime qPCR primers 
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(IDT DNA, Coralville, IA) arrived having been tested to ensure that the provided set of forward 
and reverse primers bound complementary DNA (cDNA) at the location of the gene of interest 
and reliably produced replicable qPCR results. This eliminated the need for primer verification 
and reduced the amount of cDNA derived from valuable human cells necessary to test primers. 
Sequences of PrimeTime primers (for CD36, IL-6, and reference genes described below) used 
for all subsequent experiments are available in Appendix A.  
Predesigned primers were also used to measure relative expression of reference genes. 
This decision was made due to the use of preverified primers for genes of interest, as well as to 
facilitate comparison with these experiments in future research conducted on the diabetic 
macrovascular disease BVM model. Three genes, whose functions were previously discussed in 
Chapter 1, were considered as reference genes for data analysis. The purpose of reference genes 
is to normalize activity of genes of interest to a gene that maintains consistent expression across 
treatment groups. The three reference genes analyzed by qPCR were B2M, ACTB, and HPRT1.  
 Though ideal replication behavior was expected from all pre-verified PrimeTime primers, 
preliminary evaluations were performed using methods described above for custom primers. 
Amplification for IL-6, CD36, HPRT1, and B2M was consistent across replicates, however 
ACTB displayed variability. Figure 2.4 displays amplification plots of all preverified primers. 
Figure 2.4 (“B”) denotes amplification curves for ACTB, which had greater variability than 
expected.  
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As previously mentioned, a dissociation step occurred following qPCR cycles where 
temperature was gradually increased, and fluorescence was recorded. When PCR products were 
identical, they all dissociated at the same temperature, emitting fluorescence. Multiple peaks on a 
plot of fluorescence intensity against dissociation temperature therefore demonstrated formation 
of more than one qPCR product. Due to increased variability in ACTB amplification curves, 
consultation of dissociation curves was warranted. Dissociation curves for ACTB primers had a 
peak in the non-template control well visible at a much lower temperature than the sample wells. 
This demonstrated that primers had bound together, referred to as primer-dimer formation. 
Figure 2.5 compares dissociation curves from ACTB samples to those from IL-6, which does not 
display primer-dimer formation.  
Figure 2.4: Amplification Curves of PrimeTime Preverified Primers (A)IL-6 (B)ACTB (C)B2M 
(D)HPRT1 (E)CD36. ACTB (B) displays greater variability among replicates than other sets.  
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Figure 2.5: Dissociation curves of (A) ACTB and (B) IL-6. ACTB has a peak in the non-template 
control sample, demonstrating primer-dimer formation. 
 Eliminating ACTB due to primer-dimer formation determined two target genes, IL-6 and 
CD36, and two reference genes, B2M and HPRT1. These primers were used in all subsequent 
analysis throughout this thesis. With these genes established and primers validated, data could be 
collected. Data from qPCR required processing before interpretation, however, with multiple 
data analysis methods to choose from. The following section offers comparison of data analysis 
methods and discusses the selection of the most relevant method for this thesis.  
2.3 Data Analysis Methods  
Differences in mRNA abundance can be compared using two broad approaches: absolute 
or relative quantification. Both approaches were used in this thesis. Absolute quantification relies 
on dilution assays to determine a standard curve for each reaction. In this thesis, absolute 
quantification was used to calculate reaction efficiency (E), which facilitated comparison of 
starting mRNA abundance (E-CT) where CT is cycles to threshold as determined by qPCR. 
Relative quantification traditionally relies on the simplifying assumption of perfect efficiency 
(E=2.0) and three prevalent methods are named for the values compared using this assumption: 
the 2-CT, 2
-ΔC
T, and 2
-ΔΔC
T methods [52, 53]. This section details each of these methods and their 
application to a preliminary dataset.  
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2.3.1 Preliminary Dataset Acquisition 
 Throughout this chapter, data from one experiment of the many presented in detail later 
in this thesis were utilized to compare appropriateness of various data analysis methods. Briefly, 
these data came from Human Umbilical Vein Endothelial Cells (HUVECs) (Lonza, C2519A) 
cultured in EGM-Plus media (Lonza, C5035) treated with supplemental glucose (VWR, 97062-
880) for seven days. Three glucose concentrations were compared: Basal (5.5mM), Moderate 
(10.5 mM), and High (25.5 mM) treatment groups. RNA and cDNA were isolated and 
synthesized respectively before qPCR was used to determine a Cycles to Threshold (CT) value 
for each sample. (These methods are described in more detail in the following chapter.)  
2.3.2 Absolute Quantification 
Absolute and relative quantification approaches were utilized in combination in this 
thesis in order to compare mRNA expression. Efficiency values (E) were first determined by 
absolute quantification before relative quantification methods were compared with and without 
the assumption of perfect efficiency. Serial dilutions of cDNA from Basal treatment groups were 
used as templates in otherwise identical reactions. CT values were plotted against dilution factor 
and a line of best fit was determined where the slope of this line is equal to 
−1
log 𝐸
. E is the 
efficiency of the qPCR reaction, or how many copies of a gene were made from each template 
strand during each cycle. A complete protocol for qPCR for absolute quantification and 
efficiency calculation is available in Appendix C. 
2.3.3 Relative Quantification 
There are three primary comparisons that can be made using relative quantification 
depending on conditions met. If efficiency is assumed to be optimal, 2-CT comparisons can 
demonstrate which mRNA have the highest starting abundance. If a treatment can be compared 
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to an untreated condition, 2-ΔCT comparisons are appropriate. The 2
-ΔC
T comparison can also 
demonstrate how multiple genes relate to a stable group of reference genes. With a stable set of 
reference genes and an untreated condition, fold change or 2-ΔΔCT comparisons are appropriate. 
These fold change comparisons are most physiologically relevant [45, 46]. Table 2.2 summarizes 
relative quantification data analysis methods and the assumptions required by each method.  
These methods are discussed in more detail in the following sections. 
Table 2.2: Relative Quantification Methods 
Method Assumptions 
2-CT E=2 
2-ΔCT (treatment-control) E=2  
2-ΔCT (target-reference) E=2, stable reference  
2-ΔΔCT E=2, stable reference  
2.3.3.1 The 2-CT Method 
 The most direct comparison of CT value is facilitated by 2
-C
T assessment. This 
method assumes ideal PCR efficiency—that during every cycle, two copies of each template 
strand are made and represent treatment groups as individual data points rather than 
comparisons. This is less likely to show spurious trends in small sample sizes than comparative 
methods [61]. 2-CT comparisons are especially relevant to determination of reference gene 
expression across treatment groups [60]. If 2-CT values differ significantly, reference genes may 
be unsuited for use as reference genes in later analysis. 2-CT evaluation is the most direct method 
of assessing relative mRNA abundance.  
2.3.3.2 The 2-ΔCT Method 
To evaluate the change from a negative control or Basal condition to a treated (Moderate 
or High) condition, the 2-ΔCT value was compared where 
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∆𝐶𝑇 = 𝐶𝑇(𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) − 𝐶𝑇(𝑏𝑎𝑠𝑎𝑙). 
Comparison between expression of the same gene across a treated and untreated group with the 
same starting cDNA amount as determined by UV spectroscopy is best represented by the 2-ΔCT 
value [61]. This evaluation was used to determine influence of a treatment on gene expression.  
2.3.3.3 The 2-ΔΔCT Method 
If consistent reference gene expression had been validated, comparison of 2-ΔΔCT values 
would describe fold change and facilitate expression comparisons across genes (e.g. “Gene X is 
upregulated 4-fold while Gene Y is only upregulated 2-fold”). 2-ΔΔCT value was calculated from 
expression of a target gene (GOI) and the expression of a reference gene [62] (REF) using the 
following equation: 
∆∆𝐶𝑇 = { (𝐶𝑇(𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡, 𝐺𝑂𝐼) − 𝐶𝑇(𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡, 𝑅𝐸𝐹)) − (𝐶𝑇(𝑏𝑎𝑠𝑎𝑙, 𝐺𝑂𝐼)
− 𝐶𝑇(𝑏𝑎𝑠𝑎𝑙, 𝑅𝐸𝐹)) } 
Complete protocols for all relative quantification methods are available in Appendix D.  
2.4 Data Analysis Results 
2.4.1 Absolute Quantification 
 Absolute quantification was used in this thesis to evaluate the assumption of perfect 
efficiency traditionally required to perform relative quantification. Determination of reaction 
efficiency (E) for each primer set began by performing qPCR on serially diluted cDNA, resulting 
in delayed PCR progression and increased CT values for diluted samples. Figure 2.6 depicts 
absolute quantification amplification plots of IL-6, CD36, B2M, and HPRT1.  
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Figure 2.6 includes the amplification plot of a standard curve assay for B2M. This standard curve 
is analyzed in Figure 2.7 which plots cDNA dilution factor logarithmically against average CT 
value. Figure 2.7 graphs average CT versus cDNA dilution factor, where the slope of this line is 
equal to 
−1
log 𝐸
  and E is the efficiency of the qPCR reaction.  
Figure 2.6: Standard Curve Amplification Plots: Change in fluorescence intensity over time 
(Delta Rn) versus progression of qPCR (Cycle Number) for (A) IL-6 (B) CD36 (C) B2M and (D) 
HPRT1 pre-verified primers. Horizontal lines depict threshold values.  
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Genes of interest and their determined reaction efficiency by absolute quantification are 
listed in Table 2.3. Raw data and standard curves for CD36, HPRT1, and IL-6 are available in 
Appendix M.  
Table 2.3: Measured Efficiencies by Gene from Standard Curve Analysis 
Testing the primers for replication efficiency revealed that none were within the ideal 
range of 1.8 to 2.0 [60]. These measurements prevented assumption of perfect efficiency, so 
comparisons using these gene-specific E values were utilized throughout this thesis rather than 
following convention to assume E=2.  
Gene Slope CT vs. cDNA Dilution Factor Efficiency (E) 
B2M -7.4058 1.364675 
CD36 -10.493 1.245391 
HPRT1 -7.0971 1.383256 
IL6 -10.867 1.236009 
Figure 2.7: Representative Standard Curve Analysis. B2M cDNA dilution factor versus average 
CT value. Slope of the trendline is used to determine qPCR efficiency. 
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2.4.2 Relative Quantification 
2.4.2.1 E-CT Results  
E-CT comparisons demonstrated that B2M was an unsuitable reference gene due to 
decreased expression in the Moderate glucose condition and significantly increased expression in 
the High glucose condition. CD36 expression demonstrated no change due to treatment. HPRT1 
expression decreased with Moderate glucose treatment but showed no change from Basal to 
High glucose treatment. IL-6 expression decreased under Moderate glucose treatment and 
increased significantly with High glucose concentration. Neither B2M or HPRT1 displayed 
consistent expression required of reference genes, so no suitable reference is available for these 
data. Figure 2.8 depicts E-CT comparisons.  
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A B 
C D 
 
 
Figure 2.8: E-CT Analysis. (A) B2M expression decreases with Moderate treatment and increases 
with High glucose treatment. (B) CD36 expression remains consistent across treatments. (C) 
HPRT1 expression decreases with Moderate treatment. (D) IL-6 expression increases with High 
glucose treatment. All values are in arbitrary units presented as mean ± SEM. 
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 A lack of stable reference genes evident at this point prevented relative quantification 
methods based on normalization to a reference, namely E-ΔCT (target-reference) and E
-ΔΔC
T 
comparisons. This encompasses all comparisons across multiple genes. E-ΔCT (treated-untreated) 
comparisons between control and treated conditions within the same gene remained valid and 
appear in the following section.  
2.4.2.2 E-ΔCT Results 
 Comparisons between control and treated samples using the E-ΔCT facilitated comparison 
of moderate and high glucose treatments within each gene. Expression of reference genes B2M 
and HPRT1 as well as target genes IL-6 and CD36 increased more with high glucose treatments 
compared to moderate glucose treatments. Figure 2.9 displays representative E-ΔCT results, 
depicting an increase in abundance of all analyzed genes between Moderate and High glucose 
concentrations relative to Basal expression. 
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Figure 2.9: E-ΔCT Analysis of 7-Day Data. (A) B2M (B) CD36 (C) HPRT1 and (D) IL-6 
expression all increased in High glucose condition compared to Moderate glucose condition 
relative to Basal. All values are in arbitrary units presented as mean ± SEM. 
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2.4.2.3 E-ΔΔCT Results 
Due to inconsistent expression of reference genes across treatments, the 2-ΔΔCT method 
was previously determined to be inappropriate for analysis of data in this thesis. Rather than 
excluding this popular method entirely, the comparisons in Figure 2.10 were performed to 
demonstrate conclusions which could be improperly deduced from these data. Comparisons 
across multiple genes require assumption of a common reaction efficiency. For clarity, the 
common E=2 assumption is utilized for this demonstration of methodology. CD36 expression 
was reported to have increased by approximately 170-fold at the moderate glucose concentration, 
which was inconsistent compared to the unchanged expression shown in E-CT analysis. IL-6 
expression changes depending on the reference gene selected, with higher expression under the 
High glucose treatment relative to B2M and under the Moderate glucose treatment relative to 
HPRT1. B2M and HPRT1 demonstrate opposite expression patterns relative to one another, 
implying that at least one of them is not an appropriate reference gene [63]. None of these 
conclusions are valid due to inconsistent reference gene expression.  
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A B 
C D 
E F 
Figure 2.10: 2-ΔΔCT Analysis of 7-Day Data. Influence of reference gene on results of 
comparative CT method. Expression of genes (A, C, E) relative to HPRT1 expression and (B, D, 
F) relative to B2M expression. All values are in arbitrary units presented as mean ± SEM. 
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 Using the standard 2-ΔΔCT analysis relative to B2M resulted in conflicting IL-6 expression 
patterns compared to 2-ΔΔCT analysis relative to HPRT1. This demonstrated that at least one 
reference gene had inconsistent expression [63]. The stability of common reference genes B2M 
and HPRT1 across elevated glucose treatments cannot be assumed, although such an assumption 
may seem validated by their use as reference genes in literature [37]. The importance of 
analyzing reference genes before relying on their expression for normalization is therefore 
paramount. Because of evaluation and normalization of RNA concentration before cDNA 
synthesis, it remained valid to perform 2-ΔCT comparisons from untreated to treated conditions 
[52, 53].  
2.4.3 Probe-Quencher Primers 
 Following data collection, it was realized that the products purchased from IDT were 
mistakenly PrimeTime Probes rather than PrimeTime Primers, indicating that in addition to 
strands designed to bookend target sequences during annealing, a probe with a fluorescent 
reporter and quencher pair was included. Probe sequences are available in Appendix A. The 
reporter molecule emits fluorescence when Taq DNA polymerase breaks the probe strand, 
separating the reporter from its quencher. The mechanism is depicted in Figure 2.11.  
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 This addition increased the likelihood of unwanted PCR product formation as probe 
strands may have interfered with ideal replication. To validate results gathered with both 
fluorescent probes and SYBR intercalating dye, preliminary experiments performed for data 
analysis method selection were repeated without SYBR. Trials instead recorded fluorescence 
from the included probes.  
Results from probe-only reactions displayed large variability and did not correspond with 
trends visible in samples evaluated using SYBR reporting. Many wells failed to report any 
fluorescence and noisy measurements required exclusion of additional wells, increasing error 
values. B2M, HPRT1, and IL-6 showed no meaningful changes in relative abundance with 
varying glucose concentration. CD36 showed higher relative abundance at the moderate 
concentration compared to basal but no change at the high glucose concentration relative to 
basal. Figure 2.12 depicts relative expression of B2M, CD36, HPRT1, and IL-6 as measured by 
probe and quencher reporting.  
Figure 2.11: Probe-Quencher qPCR Reporting Mechanism 
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 Results from probe-quencher trials displayed massive variability within treatment groups. 
No trends were replicated from SYBR green results to probe-quencher results, meaning that 
these experiments failed to validate results visible with SYBR fluorescence. Inclusion of probes 
likely reduced reaction efficiency substantially, consistent with measurements by absolute 
quantification. This necessitated use of measured E values rather than assuming perfect 
efficiency.  
2.4.4 Data Analysis Summary 
 Measured efficiency values can be substituted for assumed E in relative quantification 
methods which do not compare targets to reference genes [59]. E-ΔCT values, where ΔCT = CT 
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Figure 2.12: Probe-Quencher Reporting of 7-Day Responses. Data are presented as mean ± 
SEM.  
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(treatment) – CT (control), compare effects of various treatments on expression of each gene. This 
method was used throughout subsequent experiments.  
2.4 Discussion 
 The goal of this first aim was to establish targets for gene expression and to select a 
method for qPCR data analysis based on preliminary data. Genes of interest IL-6 and CD-36 
were selected from genome-wide association studies [33–35] to represent relevant pathway 
activity. Reaction efficiency (E) was determined by absolute quantification for each gene. 
Potential reference genes analyzed by 2-CT demonstrated too much variability across treatment 
groups for use as an internal reference. This variability prohibits use of the most powerful 
comparative CT method, 2
-ΔΔC
T comparison. For this reason, qPCR data in subsequent 
experiments had to be analyzed by comparing E-ΔCT values for each gene between treatment 
groups and basal groups.   
 Low efficiency determined by absolute quantification was inconsistent with expectations 
of preverified primers. According to Scientific Support staff at the manufacturer IDT, this is 
most likely due to the mistaken ordering of primers with probe-quencher reporters. Scientific 
Support also supplied the information that due to the preverified nature of these probe-quencher 
primer sets, the desired qPCR products would still be amplified. Theoretical understanding 
supports conclusions made from an intercalating dye regardless of probe presence, and is 
supported by concurrent use of  intercalating dyes and probes in literature [25–28]. Confidence 
in conclusions made from data gathered while using these primers is decreased by conflicting 
results seen with and without SYBR reporter, however this discrepancy is likely due to damage 
inflicted on the probe-quencher strand’s fluorescent molecules by a year of improper storage. 
Fluorescent probes are light-sensitive while primers alone are not, so storage methods for 
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standalone primers provide inadequate protection from UV rays. Had the probes been protected 
from light during storage, results likely would replicate those seen with SYBR reporting.  
Lack of consistent B2M expression was unanticipated, but increased serum B2M levels 
are correlated with mortality in diabetic nephropathy [69] which may be related to increased 
B2M mRNA abundance in high glucose conditions. HPRT1 is commonly cited as a potential 
reference gene for investigations of elevated glucose. [43, 51]. Inconsistency in expression of 
this gene may therefore be due to differences in RNA quality across treatment groups.  
 This study was limited by the lack of stable reference genes, meaning fold change 
conclusions were impossible. Utilizing the E-ΔCT method maximizes the conclusions we can 
make without stable reference genes, but determination of a group of stable reference genes is a 
priority for future studies.  
This aim contributes specific methods for design and selection of primers for qPCR 
analysis as well as a variety of data analysis protocols and the experiments for which each are 
valid. Genes of interest CD36 and IL-6 were selected along with reference genes B2M and 
HPRT1. In light of limitations due to improper primer ordering and lack of consistent reference 
gene expression, this aim selected E-ΔCT (treatment-control) values for comparison of the effects 
of different treatments on CD36 and IL-6 expression. With this foundation in place, data 
collection began.    
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3 EVALUATING GENE EXPRESSION IN RESPONSE TO INCREASED 
EXTRACELLULAR GLUCOSE 
3.1 Introduction 
The previous chapter identified genes of interest and determined the most appropriate 
data analysis method for use with probe-quencher primers and without consistent reference gene 
expression. With this foundation, effects of glucose concentration and treatment duration were 
investigated. As discussed in Chapter 1, glucose concentrations (5.5 mM, 10.5 mM, and 25.5 
mM) were selected to represent the progression of diabetic macrovascular disease. In an effort to 
represent disease evolution, effect of treatment duration on expression of CD36 and IL-6 was 
evaluated by qPCR. Elevation in relative expression of CD36 and IL-6 under elevated glucose at 
these timepoints would be consistent with the acute cellular response to hyperglycemia discussed 
in Chapter 1 [5, 24, 59]. This Chapter encompasses Aim 2 of this thesis: to evaluate acute 
changes in gene expression, specifically of IL-6 and CD36 in HUVECs, due to increased 
extracellular glucose.  
3.2 Methods 
 In fulfillment of this aim, HUVECs were cultured at basal, moderate, and high glucose 
concentrations for 7 or 14 days. These timepoints were selected to represent early diabetic 
macrovascular disease progression [6] and are supported by previously published studies using 
similar timepoints to investigate cellular responses to elevated glucose [3–5]. Cells were cultured 
in media according to treatment before RNA was isolated and transcribed to complementary 
cDNA. cDNA was used in RT-qPCR to evaluate relative expression with data analysis 
techniques as described in Chapter 2 and further summarized below.  
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3.2.1 Cell Culture 
Human Umbilical Vein Endothelial Cells were obtained from Lonza Walkersville Inc. 
(Catalog number 2519A, LOT 0000470896) and cultured in EGM-2 Growth Media (Catalog 
number 3162), also from Lonza. Due to product shortages, EGM-Plus Growth Media (Catalog 
number 5035) with supplemental L-Glutamine (VWR, Catalog number 16777-162) at a final 
concentration of 10 mM was substituted when EGM-2 Growth Media was unavailable. Cells 
were cultured at 5% CO2(manually measured daily with Fyrite Gas Analyzer), 80% relative 
humidity and 37° C. Cell culture media was changed every 48-72 hours throughout culture and 
all experiments were conducted on cells subcultured from the same source vial at passage 5. 
Culturing took place in T-75 flasks passaged at a 1:3 ratio and were 80-100% confluent at the 
time of RNA isolation, yielding approximately 6-8 million cells.  
Induction of high glucose conditions consisted of adding 80 mM sterile glucose solution 
(VWR Catalog number 97062-880) to final concentrations of 10.5 mM and 25.5 mM glucose, as 
described in Chapter 1. Detailed protocols for cell thawing, passing, feeding, and freezing can be 
found in Appendix E.  
3.2.2 RNA Isolation 
In order to analyze relative expression of certain genes, total RNA was isolated from cells 
using RNEasy Mini Kit (Qiagen Catalog number 74106). Once T-75’s reached 80-100% 
confluence, 3 mL trypsin (Sigma, T3924) cleaved cells from culture vessels. Centrifugation and 
aspiration of trypsin and cell media was performed before cells were resuspended in PBS 
(ThermoFisher, 14190359) and flash-frozen in liquid nitrogen. 
To begin RNA isolation, cells were first chemically lysed in a buffer containing 
chaotropic salts to release contents before being transferred to a biopolymeric spin column 
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(QIAshredder, Qiagen) to further homogenize cell lysate. Lysate was further separated by 
centrifugation through silica spin columns. Silica immobilized nucleic acids while allowing 
lipids, proteins, and cell fragments to pass through. RNA remained bound to silica through two 
washing steps which removed DNA and other residual contaminants by first modifying the salt 
concentration to make DNA insoluble and second washing with ethanol to remove salt. RNA 
was released from silica in Milli-Q pure water due to intermolecular interactions of RNA 
molecules and water molecules.  
RNA was then assessed for purity by ultraviolet-visible (UV-Vis) spectrophotometry 
using a NanoDrop 2000 (ThermoFisher). This device measures the absorbance of isolated RNA 
samples at 260 nm to determine concentration using the Beer-Lambert equation and measures 
absorbance at 280 nm to determine purity by comparing absorbance at 260 nm over absorbance 
at 280 nm. RNA with a 260/280 ratio of 1.95-2.05 can used to transcribe cDNA. Detailed 
protocols for RNA Isolation and RNA Purity Assessment can be found in Appendix F.  
3.2.3 cDNA Synthesis 
 Following isolation, RNA was transcribed into complementary DNA (cDNA) by reverse 
transcription using iScript cDNA Synthesis Kit (BIO-RAD, Catalog number 1708890). The kit 
uses both single-stranded sequences of deoxythymine nucleotides (oligo-dT) and random 
sequences of six nucleotides (random hexamer) primers to bind template strands of RNA. 
Reverse transcriptase binds double-stranded primed segments of RNA and synthesizes cDNA 
which is subsequently amplified during qPCR. Detailed protocols for cDNA synthesis can be 
found in Appendix G.  
cDNA was combined with primers, probes, Taq polymerase, dNTPs, SYBR, and 
enhancers for qPCR. Recall from the previous chapter that probes were mistakenly purchased 
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with primers and should not be included in the future. qPCR proceeded according to methods 
described in the previous chapter. Briefly, reaction mixes were cyclically heated and cooled in a 
thermocycler equipped to record fluorescence of SYBR green intercalating dye. Fluorescence 
increased predictably over 40 cycles of qPCR, facilitating determination of a CT value 
representative of starting mRNA concentration. CT values were compared by E
-ΔC
T or “Measured 
Efficiency” as described in the previous chapter. To demonstrate the importance of measuring 
efficiency by absolute quantification, comparisons using the prevalent assumption of perfect 
efficiency (E=2) or “Assumed Efficiency” were also conducted.  
Gene expression was compared by qPCR for genes of interest CD36 and IL-6 as well as 
reference genes B2M and HPRT1. Due to inconsistent reference gene expression across 
treatment groups, comparisons to reference gene expression were not conducted. Multiple 
experiments were conducted, each evaluating HUVEC responses to three concentrations of 
glucose in cell culture media. Basal (5.5 mM) acted as a control while Moderate (10.5 mM) and 
High (25.5 mM) concentrations induced varying degrees of elevated glucose conditions. An 
overview of experimental time points and the number of cell culture flasks evaluated, or 
“Independent Trials” as well as replicate qPCR samples, or “Technical Replicates” is provided in 
Table 3.1. In this table and throughout this chapter, evaluations are listed alphabetically by gene 
name for convenience.    
Differences between groups were assessed by ANOVA of CT values in JMP [72]. 
ANOVA comparisons can be found in Appendix L. Data are presented as mean ± standard error. 
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Table 3.1: Experimental Design for qPCR Experiments 
   
Independent 
Trials 
Technical 
Replicates 
Sample 
Size (n) 
Replicates 
Evaluated for 
Each 
Treatment  
7 Day B2M 2 3 6 
CD36 3 3 9 
HPRT1 3 3 9 
IL-6 3 3 9 
14 Day B2M 2 3 6 
CD36 2 3 6 
HPRT1 2 3 6 
IL-6 2 3 6 
3.3 Results 
When evaluated at seven days, relative expression of B2M decreased compared to the 
basal condition at the moderate glucose concentration while expression increased in the high 
glucose concentration. CD36 expression remained low and relatively consistent across treatment 
groups. Relative expression of HPRT1 decreased with moderate glucose treatment and was 
consistent at the high glucose concentration relative to the basal glucose treatment. Expression of 
IL-6 showed no change at the moderate glucose concentration and increased at the high glucose 
concentration (p<0.001). Assumed efficiency values used 𝐸 = 2 while measured efficiency 
values used efficiencies determined for each gene in Chapter 2, which are repeated below in 
Table 3.2. 
Table 3.2: Measured Efficiency Values from Chapter 2 
Gene Efficiency (E)  
B2M 1.364675 
CD36 1.245391 
HPRT1 1.383256 
IL-6 1.236009 
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Figure 3.1 depicts relative abundance (E-CT) of B2M, CD36, IL-6, HPRT1, and CD36 after seven 
days of treatment at 5.5 mM (Basal), 10.5 mM (Moderate), or 25.5 mM (High). 
 
Evaluation of relative gene expression at 14 days was consistent with results at seven 
days. B2M expression increased at the highest glucose concentration as did relative expression of 
IL-6 (p<0.001). HPRT1 expression was more consistent across treatment groups at fourteen days 
Figure 3.1: Relative Abundance Comparisons Between Assumed and Calculated Efficiency 
Values after 7 Day Treatment. (A)B2M expression increased at High glucose concentration. (B) 
CD36 expression remained consistent across treatment groups. (C) HPRT1 expression remained 
consistent across treatment groups. (D) IL-6 expression increased at High glucose 
concentration. Data are presented as mean ± SEM.  
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than seven days. CD36 displayed very low expression and relatively consistent expression across 
treatment groups. Figure 3.2 shows relative expression of gene targets after 14 days of treatment.  
 
3.4 Discussion 
This aim sought to compare gene expression results between basal and elevated glucose 
conditions at seven and fourteen days. Expression of mRNA for cytokines CD36 and IL-6 was 
analyzed by qPCR. CD36 expression remained consistent across elevated glucose treatments 
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Figure 3.2: Relative Abundance of Target Genes at 14-day Timepoint. (A) B2M expression 
increased with High glucose treatment. (B) CD36 expression was unaffected by glucose 
treatment. (C) HPRT1 expression decreased with Moderate glucose treatment but remained 
consistent from Basal to High glucose treatment. (D) IL-6 expression increased with High 
glucose treatment. All data are in arbitrary units and are presented as mean ± SEM. 
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indicating that either treatment intensity or treatment duration may be insufficient to induce 
CD36 upregulation in HUVECs with high glucose culture. This finding was inconsistent with 
documented work showing increased CD36 expression with elevated glucose treatment in human 
microvascular endothelial cells, however these evaluations were performed following 24 hours 
of treatment [31]. Dose- and duration-dependent PKC upregulation following glucose treatment 
of HUVECs for 7 and 14 days [73] implies upregulation of both CD36 and IL-6 through 
connected pathways [50, 66, 67]. Differential expression of CD36 across various endothelial cell 
sources is the most likely explanation for low CD36 expression regardless of treatment. 
Macrovascular ECs, including HUVECs, have substantially lower CD36 expression than 
microvascular endothelial cells (MVECs) [76]. HUVECs were characterized as lacking surface 
CD36 expression [77], suggesting low CD36 mRNA production. This validates low levels of 
expression detected in this thesis, offering support to these analysis methods. While analysis of 
CD36 expression in HUVEC under high glucose conditions offers no insight into accuracy of the 
diabetic macrovascular disease blood vessel mimic model, CD36 expression could be used in the 
future to evaluate alignment of BVM expression with macrovascular vessel expression.  
 IL-6 mRNA abundance was found to increase in HUVECs treated with 25.5 mM glucose 
at 7 and 14 days, which is consistent with gene expression in Type 2 Diabetes [70, 71]. IL-6 
upregulation appeared similar in magnitude to upregulation of B2M, however without a 
consistently-expressed reference gene there is no valid method by which to compare expression 
of B2M and IL-6 [60]. Though B2M was initially included as a potential reference gene, as 
mentioned briefly in the previous chapter, serum B2M levels are correlated with mortality from 
diabetic vascular diseases [69]. Though increased B2M mRNA expression under high glucose 
conditions has yet to be described, this may partially account for its increase. While lacking a 
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control may limit the conclusions drawn from these data, the trends present suggest that the 
documented increase in B2M expression is genuine and should disqualify B2M for use as a 
reference gene in elevated glucose condition studies.  
The lack of a stable reference gene and a common reaction efficiency required that IL-6 
upregulation be evaluated only in comparison to the untreated control. IL-6 expression increased 
by approximately 250% at 7 and 14 days in 25.5 mM glucose, which correlates well with a 
significant increase in HUVEC IL-6 mRNA expression after 14-day treatment at 20 mM glucose 
compared to 5 mM as evaluated by Northern blotting [79]. While lack of a stable reference gene 
also limits conclusions possible from these data, consistency with previously documented work 
supports that upregulation of IL-6 following implementation of increased extracellular glucose 
conditions is valid. This finding supports the hypothesis that oxidative stress can be detected 
following administration of supplemental glucose by assessing IL-6 mRNA expression in 
HUVECs.  
mRNA expression of all genes was reduced under the Moderate glucose treatment. This 
trend is inconsistent with signaling cascade-based predictions and was visible in all samples, 
raising doubts about its validity. All samples in each treatment group were transcribed from 
RNA to cDNA simultaneously, suggesting that experimental error may have caused all of these 
transcription reactions to fail. Failure to include enough Reverse Transcriptase in these reactions 
would yield low cDNA, accounting for the very low expression in every gene investigated. This 
means that conclusions cannot be made from this model about the effect of 10.5 mM glucose 
treatment on mRNA expression, however conclusions involving basal (5.5 mM) and high (25.5 
mM) glucose treatment groups remain valid.  
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Low qPCR reaction efficiency challenges confidence in these results, as mentioned in the 
previous chapter. It was determined that low reaction efficiency was due to mistaken ordering of 
probe-quencher primers. The preverified nature of these primers ensures desired PCR products 
are amplified regardless of poor efficiency and that though unwanted products may be formed 
due to probe-quencher inclusion, they cannot be exponentially amplified. This is further 
validated by evaluation of dissociation curves mentioned in Chapter 2. Heating PCR products 
after amplification demonstrated approximate uniformity in the dissociation curves of each 
sample, suggesting similar size and composition. This supports results calculated using measured 
efficiency values. In the larger context of this thesis, these data support supplemental 
extracellular glucose as a component of a diabetic macrovascular disease model as measured by 
acute upregulation of IL-6. Future work based on these findings will be further discussed in 
Chapter 5.  
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4 EVALUATING ROS GENERATION IN RESPONSE TO INCREASED 
EXTRACELLULAR GLUCOSE   
4.1 Introduction 
Chapter 2 established a methodology for gene expression analysis. Chapter 3 focused on 
measuring gene expression in response to elevated glucose at 7 and 14 days of treatment. Next, 
evaluation of Reactive Oxygen Species (ROS) generated at 24 and 48 hours was performed in an 
attempt to capture a more acute aspect of the cellular response to high glucose concentrations. 
ROS is generated more immediately than mRNA expression changes, permitting a shorter 
treatment duration, though ROS production remains elevated throughout exposure to high 
glucose [80]. Elevated glucose at 25 mM has been shown to gradually increase ROS generation 
in bovine aortic endothelial cells following three to 24 hours of treatment [81]. ROS 
overproduction and decreased DNA synthesis were detected in HUVECs treated with 28 mM 
glucose for 48 hours [82]. This aim evaluated oxidative stress responses to short-term elevated 
glucose treatment by quantifying ROS generation and cell viability at 24 and 48 hours. 
Oxidative stress induced by extracellular hyperglycemia causes endothelial damage in 
two ways: by decreasing available antioxidants and by production of reactive oxygen species 
(ROS). ROS upregulate formation of advanced glycation end products and activate the protein 
kinase C (PKC) pathway [35]. This asserts that upregulation of IL-6 detected at 7 and 14 days by 
qPCR previously in this thesis can be connected by known signaling pathways to overproduction 
of ROS at the same glucose concentrations.  Figure 4.1 depicts the process from transport of 
glucose through the endothelial cell membrane to tissue damage. Detection of ROS in 
endothelial cells reflects increased endothelial damage and associated macrovascular injury [34, 
61, 62].   
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Figure 4.1: Increased Extracellular Glucose Increases ROS Generation and Subsequent Tissue 
Damage [35]. Glucose transport initiates glycolysis which increases oxidant generation. 
Reactive Oxygen Species (ROS) are a byproduct of oxidant generation and induce tissue damage 
by increasing Advanced Glycation End-products (AGEs) and upregulating the PKC pathway. 
  
Evaluations of ROS generation in this chapter build upon previous experiments by 
detecting imbalances in cellular oxidation and antioxidation. This imbalance is termed oxidative 
stress, a precursor to endothelial dysfunction and diabetic macrovascular disease [14]. As 
previously mentioned, ROS produced during oxidative stress upregulate PKC and contribute to 
AGE formation [35]. IL-6 is directly upregulated by PKC and indirectly upregulated by AGE 
formation, associating increased ROS with increasing IL-6 mRNA expression [51, 66]. 
Additionally, measuring cell viability in response to elevated glucose is a direct metric of 
progression of endothelial dysfunction because apoptosis is upregulated as oxidative stress 
worsens [9, 10]. Decreasing cell viability in vitro under high glucose conditions has been 
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documented [82], so replication of these results would establish confidence in this imaging 
method.  
 Following validation of these methods, fluorescent staining evaluations for oxidative 
stress and endothelial dysfunction could be applied to blood vessel mimics. Visual methods for 
assessing ROS generation and cell viability in a diabetic BVM following device implantation 
would contribute to determining how well the diabetic BVM models replicate diabetic 
macrovascular disease conditions where ROS generation is high and cell viability is decreased 
[28, 78].  
4.2 Methods 
 In order to evaluate ROS generation due to elevated glucose, HUVECs were cultured in 
basal, moderate, and high glucose concentration medias for 24 or 48 hours in cover glass-
bottomed eight well plates according to methods described below. Fluorescent staining indicated 
the presence of ROS and was captured and quantified by confocal microscopy.     
Imaging experiments were conducted using a Confocal Laser Scanning Microscope 
(Fluoview 1000, Olympus). Confocal microscopy uses lasers and optical filters to emit light at a 
specific wavelength suited to excite fluorophores of a given dye. When excited at the correct 
wavelength, fluorophores emit light at a predictable lower wavelength. This light is isolated with 
optical filters, and photons are then counted by the microscope’s photo multiplier tube. The 
number of photons counted at each pixel location is assembled into an image. In these 
experiments, widefield imaging was used to locate the center of each well, and then a 20X 
magnification Z-stack was taken for each sample.  
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4.2.1 Experimental Design 
 The methods described above were carried out in two experiments. The first experiment 
assessed the effect of treatment duration. The second experiment attempted to isolate the effect 
of elevated glucose and ROS overproduction on cell viability by evaluating all samples after 48 
hours of treatment [82]. Table 4.1 lists experiments with their treatment groups and staining 
concentrations.  
Table 4.1: Experimental Design 
Experiment  Treatment  Sample Size Staining Concentrations 
Experiment 1 Basal, 24 Hours 4 Hoechst: 1 µM 
EthD-1: 1 µM 
H2DCFDA: 1 µM 
Basal, 48 Hours 7 
Moderate, 24 Hours 6 
Moderate, 48 Hours 5 
High, 24 Hours 6 
High, 48 Hours 5 
Positive Control, 48 Hours 2‡ 
Experiment 2 Basal, 48 Hours 7 Hoechst: 2 µM 
EthD-1: 1 µM 
H2DCFDA: 1 µM 
Moderate, 48 Hours 8 
High, 48 Hours 8 
Positive Control, 48 Hours 8 
‡ Excluded from results due to low sample size 
The first experiment yielded oversaturated images; adjustments to alleviate this were 
made for the second experiment. Table 4.2 lists dyes with their excitation and emission 
wavelengths as well as microscope settings for the first imaging experiment.  
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Table 4.2: Dyes and Imaging Settings for Experiment 1 
Dye Name Excitation/Emission 
Wavelength (nm) 
Filter Used Laser 
Setting (%) 
High Voltage 
Setting 
Hoechst 33342 350/461 DAPI 18.0 700 
Carboxy- 
H2DCFDA 
495/529 Alexa 
Fluor 488 
15.0 700 
Ethidium 
Homodimer 
528/617 Alexa 
Fluor 594 
15.0 700 
 Table 4.3 lists dyes and their imaging settings for Experiment 2. Laser power was 
reduced substantially for EthD from the first experiment to the second while Hoechst laser power 
and voltage were increased in attempts to equalize saturation.  
Table 4.3: Experiment 2 Imaging Settings 
Dye Name Laser Setting (%) High Voltage Setting  
Hoechst 33342 20.0 800 
Carboxy-H2DCFDA 15.0 750 
Ethidium Homodimer 1.0 675 
4.2.4 Cell Culture for Confocal Microscopy  
 Cell culture for confocal imaging was performed as described for qPCR on specialized 
culture plates. HUVECs (Lonza, C2519A) were thawed into T-75 flasks and cultured in Lonza 
EGM-Plus cell media at 5% CO2 and 80% relative humidity. Upon reaching 70 to 80% 
confluency, they were passed into cover glass-bottomed 8 well plates (Thermo Scientific, 
155411) with a seeding density of approximately 2,500 cells per well. Passing occurred 72 hours 
before staining. Treatment of 48-hour samples began 24 hours after seeding and treatment of 24-
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hour samples began 24 hours later. Cells were checked for morphological changes and 
confluency before each treatment. A detailed protocol for cell culture for confocal imaging is 
available in Appendix J.  
4.2.2 ROS Generation Assessment 
The Image-IT LIVE Green Reactive Oxygen Species Detection Kit (ThermoFisher, 
Catalog number I36007) was used to compare ROS generation between treatment groups. The 
kit contains 5-(and-6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA), 
Hoechst 33342, tert-butyl hydroperoxide (TBHP), and dimethylsulfoxide (DMSO). Carboxy-
H2DCFDA dissolved in DMSO permeates cells, within which it is cleaved by cellular esterases. 
Cleaved fluorescein compounds then fluoresce proportionally to the amount of circulating ROS 
within the cell. Live and dead cells stained green throughout this thesis have therefore generated 
substantial ROS. TBHP is a known inducer of ROS generation and, when used before carboxy-
H2DCFDA staining, serves as a positive control. Hoechst 33342 was used in viability 
assessment, described below. 
Following incubation in treatment conditions, cell media was gently rinsed from positive 
control wells. TBHP solution was added to positive control wells for 60 minutes, at which time 
the TBHP solution and media from all other wells were removed. Each well was gently rinsed 
with PBS and carboxy-H2DCFDA staining solution was added to each well for 20 minutes. After 
20 minutes, Hoechst solution and EthD solution were added to each of the wells for 10 minutes. 
Images were taken immediately following staining. A detailed protocol for evaluation of ROS 
generation can be found in Appendix H.  
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4.2.3 Viability Assessment 
 Cell viability is a ratio of live cells to total cells and is commonly used to quantify the 
health of a sample group of cultured cells [40]. Hoechst 33342, a blue nuclear stain also known 
as bisbenzimide, binds the minor groove of double-stranded DNA, creating a concentrated area 
of fluorescence within each cell’s nucleus. The number of visible blue nuclei can therefore be 
used to represent the total number of cells present. Ethidium Homodimer 1 (EthD) is a red 
fluorescent molecule which intercalates double-stranded DNA but cannot penetrate an intact cell 
membrane. Cell membranes are essential for survival, so concentrated areas of red fluorescence 
signal the presence of a dead cell. Cell viability can be calculated using the following equation 
[40].  
𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =
𝐻𝑜𝑒𝑐ℎ𝑠𝑡+𝐶𝑒𝑙𝑙𝑠 − 𝐸𝑡ℎ𝐷+𝐶𝑒𝑙𝑙𝑠
𝐻𝑜𝑒𝑐ℎ𝑠𝑡+𝐶𝑒𝑙𝑙𝑠
× 100  
Measurements of cell viability were taken from the same samples evaluated for ROS generation 
which were stained using the combined procedure described above. A detailed protocol for 
assessment of cell viability can be found in Appendix I. 
4.2.5 Image Processing and Analysis 
Cell counting and fluorescence intensity measurements were conducted in ImageJ [87]. 
Exported Multi-TIFFs were separated by channel into single-color stacks before being Z-
projected to create three images, each with all of the cells that stained positively in that color 
channel. Images were then thresholded to black and white using the “Default” threshold setting, 
and the automatic particle analyzer counted all particles greater than 0.001 cm2. This method was 
developed to maximize signal-to-noise ratio and to minimize measurement bias by eliminating 
subjective decision-making. Masks were made from thresholded images to facilitate 
measurement of mean gray value within carboxyl H2-DCFDA-positive areas. Mean gray values 
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were normalized to measured area of masks. Detailed protocols for confocal imaging including 
macros for image processing can be found in Appendix K.  
4.2.6 Statistical Analysis 
Analysis for statistical significance was conducted using JMP [72]. Analysis of variance 
(ANOVA) compared mean cell viability and mean carboxy-H2DCFDA intensity of stained areas 
over treatment groups (Basal, Moderate, or High glucose) and treatment lengths (24 or 48 hours). 
Post-hoc Tukey-Kramer HSD tests were performed to determine differences between groups. 
Raw data from statistical analysis is available in Appendix M.  
4.3 Results 
 The first experiment compared cell viability and ROS generation across 24– and 48–hour 
treatment durations for HUVECs in Basal and elevated glucose (Moderate and High) media. 
Independently, the effects of treatment and duration had no effect on cell viability (both p>0.1). 
A trend toward significant interaction effects of treatment and duration was noted (p=0.056). 
Figure 4.2 shows cell viability (live cell count/total cell count) as a function of treatment (Basal, 
5.5 mM; Moderate, 10.5 mM; High, 25.5 mM) and duration (24 or 48 hours). Tukey’s test found 
no differences between groups. 
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Figure 4.2: Viability by Treatment and Duration. In Basal (5.5 mM) glucose condition, viability 
increased between 24 and 48 hours. Neither Moderate (10.5 mM) nor High (25.5 mM) glucose 
condition displayed change in viability between 24 and 48 hours. 
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This experiment produced images that were largely oversaturated because laser power 
was too high. Oversaturation is evident in the EthD channel of these images, recognizable by the 
uniform color intensity across all stained areas of Figure 4.3C. 
Figure 4.3: Representative Images from Experiment 1. (A) Hoechst 33342-positive (B) Carboxy-
H2DCFDA-positive (C) EthD-1-positive and (D) Composite images of basal (5.5 mM glucose) 
treatment condition after 48 hours. 
A 
 
B 
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ROS generation analysis showed no change in mean gray value of stained regions using 
Tukey’s HSD test. No significant effects of treatment, duration, or interaction effects were 
detected. ROS evaluation by mean gray value is presented in Figure 4.4 with Positive Control 
indicating wells which received TBHP treatment, a known inducer of ROS [88].  
 
 Following inconclusive results of Experiment 1, adjustments were made to increase 
Hoechst concentration during staining and to optimize laser power settings. Experiment 2 also 
eliminated the 24-hour timepoint to increase sample size and potentially decrease variability. 
This decision also eliminated the possibility of interaction effects between treatment and 
duration.  
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Figure 4.4: ROS Generation as Mean Gray Value by Treatment and Duration. Samples were 
treated with Basal (5.5 mM), Moderate (10.5 mM), or High (25.5 mM) glucose. Positive Control 
samples received Basal glucose treatment and TBHP treatment for ROS generation. 
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 No statistical effect of treatment on cell viability was detected (p>0.1) in Experiment 2. 
Tukey’s HSD test found no differences between groups, including Positive Control samples. 
Figure 4.5 displays cell viability by treatment following 48 hours of incubation.  
 
Figure 4.5: Cell Viability by Treatment at 48 Hours. Positive control samples were cultured with 
basal (5.5 mM) glucose before TBHP treatment which may decrease cell viability. Basal (5.5 
mM), Moderate (10.5 mM) and High (25.5 mM) glucose treatments show no effect on cell 
viability. 
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Figure 4.6 displays representative images for Experiment 2. Images from Experiment 2 
did not display the same degree of oversaturation as those from Experiment 1, signifying 
appropriate imaging settings.  
Figure 4.6: Representative Images from Experiment 2. (A) Hoechst 33342-positive (B) Carboxy-
H2DCFDA-positive (C) EthD-1-positive and (D) Composite images of basal (5.5 mM glucose) 
treatment condition after 48 hours. 
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ROS generation was compared across basal and elevated glucose conditions. These 
results are separated by imaging day because staining duration, UV exposure, and ambient 
temperature fluctuated slightly across days; comparing fluorescence intensity can be rendered 
meaningless by any of these variables [89].  
No differences in ROS generation were detected by Tukey’s HSD test across treatment 
groups after 48 hours of treatment (p>0.1). No differences were detected across experiment days 
(p=0.062). Figure 4.7 compares Mean Gray Value of carboxy-H2DCFDA-positive areas as 
measured by macros found in Appendix K. 
 No statistically significant differences define these measurements of ROS generation or 
cell viability.  Differences due to day of assessment and interaction effects were all insignificant. 
This facilitates combination of all data from this experiment to assess treatment effect. 
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Figure 4.7: ROS Generation on (A) Day 1(n=4 per group) and (B) Day 2 (n=4 per group) of 
Experiment 2.  Samples were treated with Basal (5.5 mM), Moderate (10.5 mM), or High (25.5 mM) 
glucose. Positive Control samples received Basal glucose treatment and TBHP treatment for ROS 
generation. 
  
 
67 
 
Summarized results of each one-way ANOVA are provided in Table 4.4 while complete results 
are available in Appendix L.  
Table 4.4: Summary of Statistical Significance of Imaging Findings 
Variable P-Value Degrees of Freedom 
Cell Viability 0.2965 30 
Mean Gray Value of ROS-
Stained Areas 
0.6210 30 
4.4 Discussion 
 Aim 3 was to evaluate Reactive Oxygen Species (ROS) generation at two acute 
timepoints in elevated glucose conditions by quantifying oxidative stress activity. To this end, 
ROS generation and cell viability were visualized by fluorescent staining using Hoechst 33342, 
Ethidium Homodimer-1, and Carboxy-H2DCFDA to identify cell nuclei, dead cells, and ROS 
fragments respectively.  
 Viability measured the calculated number of live cells (Hoechst+ cells – EthD-1+ cells) 
divided by total cells (Hoechst+ cells) and represents overall well-being [40]. Viability was 
measured across 24- and 48-hour timepoints at Basal and two high glucose (Moderate and High) 
culture conditions. Cell viability was consistent across glucose concentrations and treatment 
durations. Viability decreased in positive control samples treated with TBHP, likely due to its 
documented cytotoxicity [54, 55]. TBHP is used to induce ROS generation and can reduce cell 
viability through DNA damage [7, 8]. In general, these results are inconsistent with previously 
documented decreases in cell viability [9, 31]. These results imply that either the previous trend 
of decreasing cell viability could not be replicated by these methods or that these methods could 
not detect changes in cell viability. The two-hour duration of the staining protocol may account 
for this. Due to low staining solution volumes, these solutions rapidly cooled to the ambient 
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temperature. While removed from incubation for staining, many cells were seen by eye 
detaching from culture surfaces, indicative of ongoing cell damage. This observation and the 
lack of expected changes in cell viability suggest that inconsistency with previous findings is due 
to a failure of this staining and imaging methodology.  
 ROS generation was measured by thresholding images to select areas where ROS 
generation occurred and calculating a mean gray value for those areas. Mean gray value showed 
no difference across treatment groups, which suggests that either this imaging protocol fails to 
detect differences in ROS generation or ROS generation is equivalent following 24 or 48 hours 
of high glucose treatment. A lack of ROS generation under high glucose treatment was 
inconsistent with mechanism-based predictions. This may also be due to the two-hour duration of 
the staining protocol. As previously mentioned, staining took place outside of the temperature-
controlled cell culture environment and staining solutions cooled quickly. Low ambient 
temperature could directly increase ROS generation, as increased ROS production in response to 
hypothermia has been documented at 32°C [91]. The documented lack of difference in ROS 
generation between the Basal and Positive Control samples supports this hypothesis. Because 
both treatments cultured cells in standard media (5.5 mM glucose) and the only difference 
between these groups was treatment with TBHP, which is intended to increase ROS generation, 
the lack of difference implies that by the time cells are evaluated ROS generation cannot be 
accurately quantified.  
 Live imaging protocols like those used to obtain these data rely on the researcher’s ability 
to maintain a physiologic environment throughout staining and imaging. Without dedicated non-
sterile incubation equipment, many cells undergo stress and lysis during staining and imaging. 
These experiments highlight the importance of tailoring protocols to the equipment and resources 
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available; a fixation regimen and antibody-mediated fluorescent staining protocol might provide 
more insight into the oxidative stress pathway. Detection of oxidative stress using 
immunohistochemistry is often performed by staining for 3-nitrotyrosine, which is a byproduct 
of ROS-mediated protein modification [92]. A fixated protocol demonstrated increased 3-
nitrotyrosine staining following 24 hour treatment with 30 mM glucose in BAECs and correlated 
the increase with increased ROS [93]. Nitrotyrosine was also visualized by IHC in the umbilical 
cord vessels of women with gestational diabetes [94]. This procedure would include fixation 
prior to staining, eliminating the need to maintain a physiologic environment during staining and 
imaging.  
In the greater context of this thesis, these data fail to support the high glucose condition 
as a model for diabetic macrovascular disease. Increased ROS generation with increasing 
glucose concentration was hypothesized and could have supported upregulation of IL-6 through 
PKC activation. Cell viability was predicted to decrease with increasing glucose concentration 
due to glucose-mediated cell damage, however noise was introduced into these measurements by 
uncontrolled cell damage during staining. It is difficult to determine if the lack of differences in 
ROS generation and cell viability across treatment groups was due to cellular responses to 
treatment or was due to thermal stress induced by storage at room temperature during staining 
and imaging. Investment in non-sterile incubation for use during staining and imaging would 
resolve this problem, but the cost would be significant. Use of staining protocols which include 
fixation soon after leaving the sterile culture incubator circumvent this problem. Future work 
should investigate 3-nitrotyrosine as a target for immunohistochemical staining. Alternatively, 
the live imaging protocol could be modified to include sterilization of staining materials, which 
would enable use of cell culture incubators during staining. Either modification would decrease 
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problems with the current live imaging protocols and better represent oxidative stress activity in 
cultured cells and blood vessel mimics.  
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5 DISCUSSION AND CONCLUSION 
5.1 Summary and Aims of this Thesis 
 In contribution towards development of a tissue engineered diabetic macrovascular 
diseased blood vessel mimic, this thesis completed three aims.  
 In Aim 1, two genes of interest were determined to represent oxidative stress responses 
found in diabetic macrovascular disease. Following literature review and preliminary trials with 
custom primers, IL-6 and CD36 were selected for evaluation. Higher quality predesigned primers 
were purchased for these two genes, although these primers were mistakenly ordered with probe-
quencher reporters. This necessitated measurement of reaction efficiency to accurately compare 
treatment groups. Also in pursuit of Aim 1, qPCR data analysis methods were compared and 
reference gene stability was assessed. ACTB was eliminated due to primer-dimer formation and 
HPRT1 and B2M demonstrated inconsistent expression, implying instability in at least one 
reference gene. A lack of stable reference genes determined the gene expression analysis 
method. E-ΔCT calculations were selected to represent changes in gene expression from basal to 
elevated glucose conditions. With genes selected and analysis methodology chosen, cells were 
evaluated for responses to increased glucose.  
 In Aim 2, HUVECs were evaluated at seven and fourteen days in high glucose 
conditions. Glucose concentrations of 5.5 mM, 10.5 mM, and 25.5 mM represented healthy, 
prediabetic, and diabetic conditions respectively. CD36 expression was consistent across 
treatment groups at both 7 and 14 days while IL-6 expression increased at both time points. Low 
CD36 expression supported previous work demonstrating a lack of CD36 expression in 
HUVECs, associated with their macrovascular phenotype [77]. Increased IL-6 mRNA expression 
suggests activation of the acute oxidative stress response to high glucose. Hyperacute responses 
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to elevated glucose were evaluated next via confocal imaging to capture another aspect of the 
oxidative stress response.  
 In Aim 3, fluorescent imaging of reactive oxygen species was used to measure ROS 
generation in HUVECs treated with the same healthy, prediabetic, and diabetic glucose 
concentrations for 24 or 48 hours. No trends were evident in ROS generation across treatment 
groups including the positive control treated with a known inducer of ROS. Cell viability 
decreased with positive control treatment but was unaffected by high glucose treatment. ROS 
generation was high and viability was low overall, implying cellular damage from sustained 
exposure to suboptimal environmental conditions, namely temperature, during the lengthy 
staining procedure. Alternative evaluations for ROS generation are proposed later in this chapter.  
 Overall, this thesis contributes one method for assessing cellular responses to elevated 
glucose, one method for assessing endothelial cell phenotypes, and foundational work toward 
development of an imaging protocol to represent oxidative stress activity. Demonstration of 
increasing IL-6 expression with high glucose treatment contributes toward modeling of diabetic 
macrovascular disease in this laboratory. Measuring CD36 expression was determined irrelevant 
to assessing oxidative stress behavior in HUVECs, though this evaluation could be used in the 
future to verify alignment with macrovascular endothelial cell characteristics in cultured cells 
and BVMs. Assessment of ROS generation and cell viability by confocal microscopy was 
unsuccessful, however insights from these experiments will be used in the future to accomplish 
the overall goal of visualizing oxidative stress activity.  
5.2 Challenges and Limitations 
 Elevated glucose concentrations in cell media were made using an 80mM sterile glucose 
solution, which led to a large volume of cell media being replaced by the water-based solution. 
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The high-glucose medias therefore had decreased ionic strength and nutrient concentrations 
compared to unaltered media. This could have induced hypotonicity or starvation responses in 
treated cells, obscuring effects of increased glucose concentration. Additionally, glucose 
concentration was not measured during or following culture, so the rate of glucose utilization is 
unknown. This may have resulted in fluctuating glucose concentrations based on when cell 
media was changed.  
Previous characterizations of the diabetic macrovascular diseased blood vessel mimic  
model found increased endothelial nitric oxide synthase (eNOS) mRNA expression after 7 days 
at 10.5 mM and 25.5 mM in cultured HUVECs [28]. eNOS synthesizes nitric oxide (NO), a 
potent vasodilator, and inhibits thrombus formation on the endothelial surface [95]. Other genes 
investigated (Platelet-Endothelial Adhesion Cell Molecule (PECAM), Receptor for Advanced 
Glycation End Products (RAGE)) had no changes in mRNA expression in cultured HUVECs 
[28]. Increasing eNOS expression was validated by previous work documenting increased eNOS 
expression after 5 days of treatment at 25 mM [96]. However, attempts to elucidate signaling 
cascades have proposed that elevated glucose inhibits eNOS expression [95] and contradictory 
previous work documents no change in HUVEC eNOS expression after 24 hours [97] and 96 
hours [98] of high glucose treatment. This inconsistency in documented findings suggests that 
IL-6 may be a more meaningful indicator of oxidative stress activity than eNOS.  
 The unintentional ordering and subsequent use of primers with probe detectors reduced 
reaction efficiency substantially. This required use of E-ΔCT measurements rather than idealized 2
-
ΔC
T measurements. These comparisons remain valid, however assessments using primers with 
perfect efficiency may demonstrate more change in mRNA expression across treatment groups. 
Two reactions using the same starting cDNA but different reaction efficiencies would reach the 
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amplification threshold at different times—the high efficiency reaction would have a lower CT 
value and subsequently higher relative mRNA expression than the low efficiency reaction. qPCR 
using low efficiency may therefore underestimate the degree of change in mRNA expression due 
to high glucose treatment. The avoidance of probe-quencher primers has already been 
implemented in laboratory protocols (See Appendix B). Statements of trends throughout this 
thesis are based on E-ΔCT measurements, accounting for the mistake in primer ordering. Attempts 
to verify results with probe detection were unsuccessful, most likely due to repeated exposure to 
light over the lifespan of the primers leading to extremely high variability and poor performance 
of the fluorescent markers. Had the fluorescent probes been identified immediately, storage 
would have included protection from light.  
 Evaluation of cellular responses to elevated glucose took place at seven and 14 days for 
qPCR. Levels of mRNA expression at seven and fourteen days cannot be compared directly due 
to lack of a stable reference gene, however similar trends of increased B2M and IL-6 expression 
at 25.5 mM glucose were present at both timepoints. This is inconsistent with previous research 
which found increases in oxidative stress and PKC activity at 7 days of high glucose treatment 
and further increased expression at 14 days [73]. Seven and 14 days were selected for analysis to 
facilitate comparison to previous work in this laboratory [28] as well as documented findings 
[86, 87]. Many attempts were made to investigate gene expression at 3 days, which would better 
represent acute responses to oxidative stress. Due to repeated experimental error, none of these 
samples had adequate RNA purity for assessment by qPCR. This loss of data eliminates 
comparisons to studies using this treatment duration [88–90] and prevents insight into how early 
gene expression may change in response to elevated glucose.  
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 Evaluation of ROS generation and cellular viability were conducted first at 24 and 48 
hours and subsequently only at 48 hours. These timepoints correlate well with studies that link 
ROS overproduction with decreased cell viability or proliferation [65, 79, 85]. To better capture 
acute ROS generation responses due to high glucose conditions, shorter time points between four 
and 24 hours should have been investigated [64, 91, 92]. Regardless of treatment duration, this 
evaluation method failed to capture differences in ROS generation and cell viability across 
glucose treatment concentrations. As mentioned in chapter 4, it is impossible to determine if 
these results accurately represent cell behavior due to damage which occurred during staining 
and imaging. Due to a lack of dedicated incubation equipment for cells undergoing staining, 
samples were surrounded by ambient air for at least two hours before being imaged. This led to 
rapid cooling of cell culture media and staining solutions which increased ROS generation and 
cell death in all samples due to hypothermia [84, 97]. Rather than investing in cost-prohibitive 
incubation equipment, fixating samples immediately following high glucose treatments and 
using an antibody-based stain could be used to identify oxidative stress and ROS production. 3-
nitrotyrosine a byproduct of ROS protein modifications and is commonly used as a marker for 
oxidative stress [98, 99]. Cells in culture or BVMs could be stained for oxidative stress using this 
method in the future.  
 This thesis is also limited by the lack of BVM data. Previous investigations in this 
laboratory found differential mRNA expression between HUVECs treated in culture and 
HUVECs incorporated into a BVM [28]. As previously mentioned, eNOS was upregulated by 
high glucose treatment in HUVECs in culture, however eNOS expression was consistent across 
treatment groups in HUVEC BVMs. Additionally, RAGE expression was consistent across 
treatment groups in cultured HUVECs but was upregulated by elevated glucose in HUVEC 
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BVMs [28]. This emphasizes the role of 3D morphology and shear conditions on HUVEC gene 
expression and limits the relevance of conclusions made from cells in static 2D culture. Future 
work related to this will be addressed below. 
5.3 Future Work 
 This thesis documents sound methods for qPCR data analysis when reaction efficiency is 
suboptimal and all of the missteps that led to suboptimal efficiency. Therefore, it would serve the 
development of a diabetic macrovascular disease model to repeat some of these experiments 
using primers with ideal reaction efficiency. Notably, IL-6 mRNA expression should continue to 
be evaluated in future experiments as it represented increased oxidative stress activity due to 
high glucose treatment. In addition, introduction of an intermittent glucose treatment, where cells 
are treated with Basal and High glucose medias on alternating days, could further increase 
oxidative stress and IL-6 activity by more closely replicating acute glucose challenges in Type 2 
Diabetic patients [96, 97]. This research is based on the understanding that acute post-prandial 
hyperglycemia contributes to the pathogenesis of diabetic complications, though the mechanism 
for this association is unknown [109]. Previous work, which found increased IL-6 mRNA 
expression at 7 and 14 days of treatment with 20 mM glucose, found substantially increased 
expression following intermittent glucose treatment [79]. Replicating the oxidative stress 
response could also be enhanced by addition of tumor necrosis factor alpha (TNFα) to 
endothelial cell media [99, 100]. TNFα alone and in combination with elevated glucose 
upregulates ERK1/2 signaling, indicative of diabetic macrovascular disease similarity [102, 104, 
105]. Inclusion of intermittent glucose treatments or TNFα in culture media for the diabetic 
macrovascular disease model could further progress the model toward a diseased state.  
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 High glucose medias were made using 80 mM glucose in water, which diluted culture 
media. In the future, stock glucose solution should be made at a 2 M concentration and sterilized 
via autoclave to reduce the volume of glucose solution required in treatment medias. This will 
reduce the potential effects of hypotonicity and starvation from media dilution. Additionally, an 
osmotic control should be added to further isolate the effects of glucose concentration. Mannitol 
is a molecule which is structurally similar to glucose but is not bioactive. It is commonly used in 
studies of high glucose in cultured cells [74, 113]. Mannitol stock solutions should also be made 
at a 2 M concentration and sterilized via autoclave to avoid media dilution.  
 Rate of glucose consumption in these cells is unknown and should be characterized 
before investigations of intermittent glucose treatments begin. In order to determine how often 
cell media should be changed to maintain consistent glucose concentrations, a colorimetric assay 
(Glucose Assay Kit, Abcam ab65333) should be used to measure glucose concentration in 
treated cells incrementally until a significant decrease occurs. Cell media should then be changed 
within the duration of consistent concentration for non-intermittent treatments.  
 Sodding cells into electrospun scaffolds to create true diabetic macrovascular disease 
BVM models has been shown in this laboratory to change trends in gene expression due to 
elevated glucose [28]. This may be due to an effect of peristaltic flow on cellular responses. For 
this reason, full characterization of HUVEC BVM responses to elevated glucose and intermittent 
glucose treatments or media supplementation should take place alongside assessments of cells in 
2D culture. Following the characterization of HUVECs in culture and in BVMs, similarity to the 
disease state in vivo could be increased by evaluation of Diabetic Human Coronary Artery 
Endothelial Cells (DHCAECs) for responses to the same treatments. DHCAECs have been 
shown in this laboratory to exhibit differential responses to high glucose treatment in 2D culture 
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and in BVMs compared to HUVECs in 2D culture and in BVMs [28]. Another potential 
modification to increase similarity to the cell environment in vivo is the inclusion of smooth 
muscle cells sodded onto the scaffold before endothelial cell sodding. While dual-sodded vessels 
have been investigated previously for other applications, methods for qPCR on dual-sodded 
vessels have not been developed.    
Assessing oxidative stress by confocal imaging facilitates powerful visualizations of cell 
responses. Without stage-mounted incubators and a dedicated non-sterile incubator, cells 
undergo oxidative stress during the staining and imaging procedures. Improvement of live 
imaging protocols to better suit available equipment could reduce thermal stress experienced by 
samples. Staining solutions are sterile upon arrival, so conducting all staining inside the cell 
culture hood would allow samples to be returned to the cell culture incubator while stains 
penetrate live cells. Previous development of a low-cost microscope stage heater by Vahid 
Hamzeinejad under the guidance of Dr. Trevor Cardinal could facilitate maintaining physiologic 
temperature during imaging. Utilization of stage heaters is essential in Animal Science 
laboratories for the investigation of embryos, so commercial equipment could potentially be 
borrowed from that department in the future. Either of these options would substantially improve 
the data collected from live imaging.  
Alternative methods like immunohistochemical staining for 3-nitrotyrosine allow 
fixation, preventing cell damage before analysis. HUVECs, DHCAECs, and BVMs made from 
both cell types can all be fixated in formalin before incubation with an anti-3-nitrotyrosine 
primary antibody (e.g. Abcam, ab61932), blocking, and incubating with a complementary 
secondary antibody conjugated to a fluorescent molecule [92]. Measuring stained areas in 2D 
cultured samples and BVMs could quantify severity of oxidative stress [106]. This imaging 
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modality is better suited to equipment and resources available to this laboratory and should be 
investigated alongside development of the diabetic macrovascular disease BVM model.  
5.4 Conclusion 
 This thesis supports the method of elevated extracellular glucose as contribution toward 
an oxidative stress state in HUVECs as measured by qPCR. IL-6 expression increased, consistent 
with diabetic macrovascular disease pathology [6–8]. CD36 expression remained consistently 
low across treatment groups, which was unanticipated but validated by a documented lack of 
CD36 expression in HUVECs [81,90].  
This thesis rejects live cell imaging, as performed, for measuring ROS generation as a 
feasible method of determining oxidative stress activity in this model. Improvement of 
temperature regulation during staining and imaging would increase data relevance. Additionally, 
staining protocols that allow fixation should be investigated as a means to detect ROS generation 
in HUVECs; these protocols can be applied both in culture and in BVMs using ROS levels as an 
indicator of early oxidative stress responses.  
Cell viability also failed to decrease in response to elevated glucose as has been 
documented [44]. This could also be a result of the extended live cell evaluation. Future work to 
characterize the full diabetic macrovascular disease BVM model including evaluation of diabetic 
cells and incorporation into 3D scaffolds will progress the model toward relevant conclusions 
about vascular devices. Additional simulation of the disease state by inducing intermittent 
glucose treatments or incorporating TNFα into culture media will accentuate relevance of the 
model. Imaging protocols utilizing fixatives will minimize the effects of staining duration on 
quantitative image analysis.  
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In summary, this thesis contributes thorough comparisons of data analysis methods for 
qPCR and preliminary evaluation of changes in gene expression in response to sustained 
elevated glucose conditions. Insight into the relevance of live imaging protocols to this project 
were also provided and an alternative method was proposed. This thesis serves as a launching 
point for further characterization of the diabetic macrovascular disease BVM model.     
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APPENDIX A: PRIMER SEQUENCES 
Primer Sequences  
Custom Primers, IDT DNA "Custom Oligos" 
Gene Name Primer Sequences Amplification? 
IL-6 FOR 5'CCTTCTCCACAAACATGTAACAAGA3' 
REV 5'TCACCAGGCAAGTCTCCTCA3' 
N 
IL-6 FOR 5'TGTTACATGTTTGTGGAGAAGGAG3' 
REV 5'CTCAATATTAGAGTCTCAACCCCCA3' 
N 
CD36 FOR 5'AAGACTTTCCTGCAGAATACCA3' 
REV 5' ACAAGCTCTGGTTCTTATTCACA3' 
N 
CD36 FOR 5'TTCTGCATCTGCTCCTGCAA3' 
REV 5'ACAAGCTATGGTTCTTATTCACA3' 
N 
CD68 FOR 5'TAGCTGGACTTTGGGTGAGG3' 
REV 5'TAGCTGGACTTTGGGTGAGG3' 
Y 
CD68 FOR 5'CCAGTGCTCTCTGCCAGTA3' 
REV 5'GGTGGGATCATCTCCAGTACA3' 
N 
IL-1A FOR 5'GGCCATCTTGACTTCTTTGCT3' 
REV 5'GACGCACTTGTAGCCACGTA3' 
N 
IL-1A FOR 5'AGGCTTGATGATTTCTTCCTCTGA3' 
REV 5'AGTAGCAACCAACGGGAAGG3' 
Y 
PLA2G7 FOR 5'TAAGTTAACCGCGGGTCCAG3' 
REV 5'TTGTTGACCCATGCTGATGA3' 
N 
PLA2G7 FOR 5'GCATCAGGTCTGCGGAAAGG3' N 
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REV 5'TTTCAGCTTAGTCTCCTGGACC3' 
PTGS2 FOR 5'CAAATTGCTGGCAGGGTTGC3' 
REV 5'AGGGCTTCAGCATAAAGCGT3' 
Y 
PTGS2 FOR 5'TCCCTTGGGTGTCAAAGGTAAA3' 
REV 5'TGCCCCTCGCTTATGATCTG3' 
Y 
PPARG FOR 5'CGTGGCCGCAGAAATGAC3' 
REV 5'CACGGAGCTGATCCCAAAGT3' 
Low 
PPARG FOR 5'GCTTGGGTCGGCCTCG3' 
REV 5'CAACCATGGTCATTTCTGCGG3' 
N 
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PrimeTime® Std qPCR Assays‡, IDT DNA  
Gene Sequences 
ACTB Probe 5’/56-FAM/TCATCCATG/ZEN/GTGAGCTGGCGG/3IABkFQ/-3’ 
Primer 1 5’-CCTTGCACATGCCGGAG-3’ 
Primer 2 5’-ACAGAGCCTCGCCTTTG-3’ 
B2M Probe 5’-/56-FAM/CTGCCGTG/ZEN/TGAACCATGTGACT/3IABkFQ/-3’ 
Primer 1 5’-ACCTCCATGATGCTGCTTAC-3’ 
Primer 2 5’-GGACTGGTCTTTCTATCTCTTGT-3’ 
CD36 Probe 5’-/56-FAM/TGTAGGACC/ZEN/TCAAGACTGGCTCCA/3IABkFQ/3’ 
Primer 1 5’-TCAATTCGTCTAATCATTGGAAAGC-3’ 
Primer 2 5’-CCTGTTTACTTTCTGCATCTGC-3’ 
HPRT1 Probe 5’-/56-
FAM/AGCCTAAGA/ZEN/TGAGAGTTCAAGTTGAGTTTGG/3IABkFQ/-3’ 
Primer 1 5’-GCGATGTCAATAGGACTCCAG-3’ 
Primer 2 5’-TTGTTGTAGGATATGCCCTTGA-3’ 
IL-6 Probe 5’-/56-FAM/CAACCACAA/ZEN/ATGCCAGCCTGCT/3IABkFQ/-3’ 
Primer 1 5’-TTCTGTGCCTGCAGCTTC-3’ 
Primer 2 5’-GCAGATGAGTACAAAAGTCCTGA-3’ 
‡ Be sure to select “Primers Only” when ordering to avoid buying probes. Use SYBR reporter 
instead.  
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APPENDIX B: PROTOCOL FOR PRIMER DESIGN 
Purpose: To design primers for reference genes and genes of interest. 
Approximate 
Time: 
10-15 minutes 
per primer 
Procedure: 
1.Go to GenBank: http//www.ncbi.nlm.nih.gov/genbank/ 
2. Select “Nucleotide” from the drop-down search menu 
3.Search for the gene of interest, ensure mRNA and Homo sapiens (protein) is 
selected 
4. Select gene and scroll to the bottom of the page to locate the sequence 
5. Record the accession number and copy the gene sequence 
6. Go to PrimerQuest: http://www.idtdna.com/primerquest/home/index 
7. Copy the sequence into the “Sequence Entry” box at the top of the page (it 
will automatically ignore line numbers) 
8. Input the sequence name 
9. Select “Show Custom Design Parameters” 
a. Select “qPCR Intercalating Dyes (Primers Only) 
b. Set “Primer Size (nt)” to min. 18, optimum 20, and max. 22 
c. Set “Primer Tm” to min. 59.0, optimum 60.0 and max. 61.0 
d. Set “Amplicon Size (bp)” to min. 180, optimum 200, and max. 220 
e. Leave all other parameters as is 
f. Click “Get Assays,” PrimerQuest will output 5 sets of forward and 
reverse primers that match input criteria 
g. Select “View Assay Details” for the desired primer set. This will open a 
new page with the forward and reverse primers. Copy these sequences. 
10. Go to NetPrimer (leaving the IDT page open): 
http://www.premierbiosoft.com/NetPrimer/AnalyzePrimer.jsp 
11. Input copied forward and reverse primers, name of sequence and an 
optional description, and click “analyze” 
12. Analyze “Rating” – Ideal rating is around 95% and higher for each primer, 
however not necessary if not possible for selected gene 
13. Once a primer set with optimal ratings has been determined, go to Primer-
BLAST: http://www.ncbi.nlm.nih.gov/tools/primer-blast 
14. Enter the selected forward and reverse primers into “Primer Parameters” 
box 
15. Check for homology with non-target genes, if found select different primer 
set from PrimerQuest and repeat for each gene 
16. Once an optimal primer set has been selected, return to Primer Quest 
(Integrated DNA Technologies): http://www.idtdna.com/site 
Reminders: 
1. It is best to 
select an 
mRNA 
sequence that 
spans an 
intron in the 
DNA 
sequence (to 
prevent 
amplification 
of 
contaminated 
DNA in 
qPCR 
reaction) 
2. The first 
primer set is 
not always 
the best, 
complete all 
primer 
selection 
steps for 
multiple 
primers for 
each gene 
prior to 
making 
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selections to 
order. 
3.High 
homology 
with 
different 
variants of 
same gene is 
desirable 
 
High 
homology with 
non-target 
genes is not 
desirable 
17. Click the box for the forward and reverse primer set that meets all the 
desired parameters and you are ready to purchase and click “Add Selected 
Assays to Cart” 
18. In the pop-up that appears click “Forward and Reverse Primers”, then 
select “Oligos in Tubes” 
19. Confirm assay set and click “Continue” 
20. Change Scale to 25nmol DNA oligo 
21. Change “Purification” to “Standard Desalting” 
22. Name sequence with gene and forward/reverse 
23. Click “Add and Checkout” 
24. Once in cart, click edit on each primer sequence. Change “Normalization” 
to “Lab Ready.” Click “Add to Order” 
25. Note the size of the expected amplicons, record sequence and accession 
number as necessary 
26. Place order, each primer pair should be approximately $20 
Materials: 
1.Computer 
with internet 
access. 
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APPENDIX C: PROTOCOL FOR QPCR  
Approx. Time:  
2 hours prep, 2 hours 
run time 
Procedure: 
A.  Plate & Primer Preparation 
1. Plan out plate map 
1.1. 3 replicates for each sample per GOI + 1 NTC per GOI 
2. Calculate PMM for each GOI 
2.1. Include 10% for pipetting errors 
2.2. See Table 1 for amount needed per well 
 
Table 1: Primer Master Mix Volumes 
Solution Volume per Reaction (uL) 
Fast SYBR Green 5 
15 uM Forward Primer 2 
15 uM Reverse Primer 2 
Nuclease Free Water 7.8 
 
3. Turn on hood, and let run for at least 1 hour prior to use 
4. Spray down hood with ethanol and wipe with kim wipes 
4.1. Spray down each item (pipettes, plate holder) brought into the 
hood 
5. Prepare PMM in nuclease free tube for each GOI 
 
B. OPTIONAL: 1:2 Serial Dilution for Standard Curve 
1. Label 7 nuclease-free tubes for each batch of cDNA being assessed 
2. Dispense 4.8 µL cDNA in tube #1 
3. Dispense 1.6 µL nuclease-free water in tubes 2-7 
4. Transfer 1.6 µL from tube #1 into tube #2 
5. Repeat step 4 for remaining tubes, creating dilutions listed in Table 
2 
Abbreviations: 
1. GOI – Gene of 
Interest 
2. NTC – non-template 
control 
3. PMM – primer 
master mix 
Reminders: 
1. Use aseptic technique 
in the hood 
2. Keep qPCR master 
mix cold (on ice or in 
frozen tube rack) 
3. SYBR green is light 
sensitive, use 
precautions once 
added to PMM 
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Materials:  
1. Fast SYBR Green 
2. Fast 96-well qPCR 
plate 
3. Plate cover 
4. 15 uM primers 
5. Nuclease free water 
6. Frozen PCR plate 
holder 
7.  Ethanol 
8. Kim Wipes 
9. Micropipettes 
 
6. Discard 1.6 µL from tube 7 
Table 2: 1:2 Serial Dilution  
Tube 
Number 
Final Volume cDNA (µL) Dilution Factor 
1 3.2 1.0 
2 1.6 0.5 
3 0.8 0.25 
4 0.4 0.125 
5 0.2 0.0625 
6 0.1 0.03125 
7 0.05 0.015625 
 
C.  PCR Plate Preparation 
1. Place 96-well plate in frozen plate holder 
1.1. Change plate holder out if color change occurs 
2. Pipette 16.8 uL of appropriate PMM into each well 
3. Pipette 3.2 uL of appropriate cDNA (or dilution) into each well 
3.1. Pipette 3.2 uL of nuclease free water for NTC wells 
4. Secure plate cover onto 96-well plate 
5. Centrifuge plate briefly 
 
D. qPCR System Set Up 
1. Turn on qPCR 7500 Fast System and connected laptop 
1.1. Open 7500 Fast System software 
2. Name plate, input name and any additional notes for plate ID 
3. Select SYBR Green as detector 
3.1. Use ROX as passive reference 
4. Input sample ID and GOI for each well 
4.1. This will help with data analysis 
4.2. Select action for each well: Standard (for all samples, NTC, or 
none (for empty wells) 
5. Place plate in qPCR 7500 Fast System 
6. Use run times from Table 3 and include a dissociation cycle in the 
run 
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Table 3: Thermal Cycling Times for qPCR 7500 Fast System 
Temperature 
(ᵒC) 
Duration 
(seconds) 
Cycle 
95.0 20 HOLD 
95.0 3 HOLD 
60.0 30 40 
 
7. A pop up will notify if run was successful, save the document and 
continue with qPCR Data Analysis 
 
E. Clean Up and Storage 
1. Discard pipette tips and empty tubes in biohazard 
2. Return supplies to appropriate location 
2.1. Label properly with contact information 
3. Wipe down hood with ethanol and kim wipes before turning off 
4. Store FAST SYBR Green at 4ᵒC after first thaw 
5. Store qPCR plate at -20ᵒC after the run  
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APPENDIX D: PROTOCOL FOR QPCR DATA ANALYSIS 
Approx. Time: 
5-10 min per 
sample 
Procedure: 
 
A. Analyzing qPCR Results on 7500 Real-Time PCR System 
1. Upon completion of a qPCR run, begin by reviewing the “Spectra” tab. 
You are main concern is column “A”, this is the column that detects SYBR 
green fluorescence. Highlight all wells for a gene of interest and slide the 
“cycle” box upwards. You need to verify that fluorescence increases from 
cycle 0 to cycle 40. Figure 1 shows proper fluorescence for a gene of interest 
at 40 cycles. 
 
Figure 1: Spectra for a single gene of interest at 40 cycles. 
2. View the “Amplification Plot” tab. “Auto” calculation can be performed 
for Ct; however, you will need to verify the output to ensure that it has been 
analyzed correctly. 
2.1. Baseline should be set for cycles prior to exponential amplification that 
appears almost as a horizontal line. In figure 2, the baseline should be set for 
cycle 22 to 27. 
2.2. Place the threshold cycle (horizontal green line in figure 2) in the middle 
of the linear region. Then click “Analyze”. Figure 3 shows the same results 
after analysis. 
2.3. Click File, Export, Results. 
Abbreviations: 
1. Ct - threshold 
cycle 
2. SE - standard 
error 
3. STDEV - 
standard 
deviation 
4. n - sample 
size 
5. s - STDEV of 
ΔCt 
6. GOI - gene of 
interest 
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Figure 2: Raw amplification plot for a specific GOI. 
 
Figure 3: Amplification plot after being analyzed. 
3. Next, click the “Dissociation Curve” tab. Ensure that all wells containing 
samples are melting at the same temperature, as seen in Figure 4. 
Figure 4: Ideal dissociation curve for a specific primer. 
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3.1. Make note of any wells that did not have a similar curve or had primer-
dimer formation as seen in Figure 5. 
 
Figure 5: Dissociation curve with primer-dimer formation. 
4. Prior to data analysis, you will want to review the analyzed amplification 
plots for each triplicate set of samples for each GOI. You can do this by 
highlighting the appropriate wells on the “Amplification Plot” tab. All 
triplicate values should have similar slopes. Note: Wells with different slopes 
should be considered an outlier and removed from the data set. 
5. Lastly, you will need to review the dissociation curve for 
outliers and primer-dimer formation, and remove data as 
necessary. 
B. Reference Gene Validation 
1. Average triplicate Ct values for each sample for the reference 
gene. 
2. Plot average Ct values for each sample group on a bar chart. 
2.1. Calculate SE using the following equation for the error 
bars: 
𝑆𝐸 =
𝑆𝑇𝐷𝐸𝑉
√𝑛
 
3. Perform a one-way ANOVA with a 95% confidence interval 
to ensure there is no significant difference between samples 
for the reference gene. 
3.1. If p <0.05 the reference gene cannot be used for the 
samples. 
C. Absolute/Standard Curve Analysis 
1. Plot log10(cDNA dilution factor) vs. average CT value  
2. Calculate slope of linear trendline 
3. Calculate E by the following equation: 
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𝑠𝑙𝑜𝑝𝑒 =
−1
𝑙𝑜𝑔 10𝐸
 
4. If E=1.8-2.0 with R2=0.99, ideal efficiency (E=2) can be assumed and 2-
ΔΔC
T comparisons are appropriate 
5. If E<1.8, use measured E to compare average CT of treated and untreated 
groups with the following equation: 
∆𝐶𝑇 = 𝐶𝑇(𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) − 𝐶𝑇(𝑏𝑎𝑠𝑎𝑙) 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐴𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 =  𝐸−∆𝐶𝑇 
D. Relative Expression Analysis 
1. Average triplicate Ct values for each sample/gene of interest set. 
2. Normalize samples to the appropriate reference gene using the following 
equation: 
∆𝐶𝑇 = 𝐶𝑇(𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙) − 𝐶𝑇(𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒) 
3. To obtain ΔΔCT data, an experimental and control group must be analyzed, 
shown in the formula below: 
∆∆𝐶𝑇 = { (𝐶𝑇(𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡, 𝐺𝑂𝐼) − 𝐶𝑇(𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡, 𝑅𝐸𝐹))
− (𝐶𝑇(𝑏𝑎𝑠𝑎𝑙, 𝐺𝑂𝐼) − 𝐶𝑇(𝑏𝑎𝑠𝑎𝑙, 𝑅𝐸𝐹)) } 
 
4. Abundance and fold change can then be calculated using the following, 
respective equations: 
𝐴𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 =  2−𝛥𝐶𝑇 
𝐹𝑜𝑙𝑑 𝐶ℎ𝑎𝑛𝑔𝑒 = 2−∆∆𝐶𝑇 
E. Calculating STDEV and S 
1. Calculate STDEV for each for each sample/primer set 
(including the reference gene) 
2. Calculate s using the STDEV of the reference gene and the 
gene of interest: 
𝑠 = √𝑆𝑇𝐷𝐸𝑉𝐺𝑂𝐼
2 + 𝑆𝑇𝐷𝐸𝑉𝑅𝐸𝐹
2  
3. Calculate SE for the fold change values (for error bars) with 
the equation below: 
𝑆𝐸 =  
𝑠
√𝑛
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APPENDIX E: PROTOCOLS FOR CELL CULTURE 
Purpose: The purpose of this SOP is to guide the user in thawing and feeding cells during culturing.  
Approx. Time: 
30 min. per day 
Procedure: 
A. Preparation 
1. Assure proper lab hygiene has been followed 
2. Place cell culture media water bath to warm up 
3. “Open” the hood by raising the door to the marked 
line and turning on the light and pump 
4. Wipe down hood with 70% IPA 
5.  Wipe microscope stage with 70% IPA 
6. Check status of the cells and record confluency 
7. Place flask back into the incubator until media is 
warmed up 
8. Write down volume of cell media needed in your lab 
notebook 
8.1. Volume of media needed depends on task and 
confluency of cells 
8.2. Refer to ❶ 
 
B. Thawing 
9. “Open” the hood by raising the door to the marked 
line and turning on the light and pump 
10. Bring bottle of cell media into the hood  
11. Fill flask with appropriate amount of media  
12. Place flask in the incubator and allow to warm for 25 
minutes 
13. Open Dewar 
14. Carefully take out the correct canister and cane  
15. Located the position of the desired cell vial on the rod 
16. Take the vial off, put cane into the Dewar, and close 
the Dewar 
17. While holding the top of the vial, swirl the frozen vial 
in the water bath to thaw  
17.1. The vial may hiss and pop-- this is normal 
18. Once the vial is thawed, spray down with IPA 
19. Bring the thawed vial into the hood and loosen its cap 
20. Pipette the cell solution into flask of media  
20.1. Ensure the whole cell solution is taken 
21. Place the flask in the incubator  
 
❶                    
Thawing  
Flask Media 
T-25 9 ml 
T-75 20 ml 
 
Under 45% 
confluency 
Flask Media 
T-25 5 ml 
T-75 15 ml 
T- 225 45 ml  
 
Over 45% confluency 
Flask Media 
T-25 7.5 ml 
T-75 22.5 ml 
T- 225 67.5 ml  
 
Abbreviations: 
1. IPA – 
isopropyl 
alcohol 
2. PBS – 
phosphate  
buffered 
saline 
3. HUVEC – 
Human 
umbilical vein 
endothelial 
cell 
Reminders: 
4. Always spray 
items with 
IPA before 
placing them 
in the hood  
5. Spray hands 
with IPA 
often, 
particularly 
after taking 
them out of 
the hood. 
6. Avoid 
messiness in 
the hood 
7. Remember 
that pipettes 
can typically 
hold more 
volume than 
they are 
labeled 
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8. Be mindful of 
the cell type 
you are 
working 
with—some 
are more 
fragile than 
others 
9. Always carry 
flask tilted 
bottom end 
down  
 
C. Feeding   
22. Feed cells 12 hours after thawing and every 48 hours 
until RNA isolation 
23. Bring the cell media into the laminar flow hood 
24. Bring 45ml conical(s) into hood 
25. Uncap bottle of cell media 
26. Pour appropriate amount of media into conical(s)  
27. Recap conical(s) and place in warm water bath (37o C) 
28. Once media is warmed, bring back into hood. 
29. Bring cell flask out of incubator into the flow hood 
30. Open an aspirating pipette and connect to pump 
tubing 
31. Uncap cell flask and tilt towards one of the back 
corners ❷ 
32. Insert pipette and aspirate the media out of the cell 
flask 
32.1. Be careful not to touch the pipette against 
the flask neck 
32.2. Aspirate out all the cell media 
33. Remove pipette, cap cell flask, and dispose of the 
pipette. 
34. Open an appropriately sized pipette and attach to the 
pipette aid 
35. Pipette warmed media from conical(s) (from step 4-6) 
36. Uncap cell flask and pipette media into the flask 
37. Cap cell flask and dispose of the pipette 
38. Place cell flask into the incubator 
39. Place cell media to the refrigerator 
40.  “Close” the hood by wiping down all surfaces with 
70% IPA, turning off the pump and light, and pulling 
down the hood door to 75% closed. 
 
❷ 
 
 
Materials:  
10. 70% 
IPA 
11.  Flask 
with cells 
12. Cell 
Media - warm 
13. Pipettes 
(various sizes) 
Revision History: 
A Jakub Truty Spring 2014 
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C Gabriella Sugerman 180708 
  
  
 
110 
 
APPENDIX F: PROTOCOLS FOR RNA ISOLATION AND PURITY ASSESSMENT 
Purpose: Isolate RNA from cells or BVMs. 
Approx. Time:  
1.5 hours 
Procedure: 
A.  Preparation 
In Bonderson: 
6. Wash hands and put on gloves 
7. Spray or wipe down working area, micropipettes, and any 
other tools with RNA zap 
8. Obtain and label QIA-shredder, RNeasy spin column, and 
2 RNAse-free 1.5 mL collection tubes for each sample 
 
B.  Preparing Cells in Flasks 
In tissue engineering lab: 
6. Spray down hood with 70% IPA 
7. Warm Trypsin and corresponding media to deactivate the 
Trypsin 
8. Trypsinize cells 
8.1. Aspirate media from flask 
8.2. Waterfall PBS and rinse 
8.3. Aspirate PBS 
8.4. Add Trypsin (Sigma) 
8.4.1. T25 – 1 mL Trypsin 
8.4.2. T75 – 3 mL Trypsin 
8.4.3. T225 – 9 mL Trypsin 
8.5. Incubate for several minutes 
8.6. “Slap the flask” to loosen cells 
8.6.1. Use the microscope to ensure cells are removed 
from flask 
8.7. Deactivate with media 
9. Transfer cell solution from flask to labeled 50 mL conical 
10. Centrifuge conicals for 4 minutes at setting 4 
11. Carefully aspirate solution above cell pellet 
12. Add about 5 mL of PBS to cell pellet and resuspend 
13. Repeat steps 5 and 6 
14. Submerge conical with cell pellet in liquid nitrogen for 
about 15 seconds until frozen through 
15. Transfer to Bonderson Lab, or store at -80ᵒC 
❶  
 
 
 
❷  
 
 
 
Abbreviations: 
4. Isopropyl 
alcohol (IPA) 
5. Phosphate-
buffered saline 
(PBS) 
Reminders: 
10. Keep 
reagents on ice 
11. Maintain 
RNase-free 
environment  
Materials:  
14. Qiagen 
RNeasy Kit 
(includes 
QIAshredder 
columns, RNeasy 
columns, and 
Buffers RLT, 
RPE, and RW1) 
15. 70% EtOH  
16. RNase-Free 
water 
17. RNase-Free 
tubes 
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C. Preparing Cells in BVM 
In Bonderson: 
1. Record BVM dimensions 
2. Rinse BVM in PBS to remove all traces of media 
3. Transfer BVM to 1.5 mL collection tubes 
D. RNA Isolation 
In Bonderson: 
1. Add 600 uL of Buffer RLT to sample 
1.1. Pipette up and down to mix 
1.2. Vortex tube for 2 minutes 
1.3. For BVMs, add half the volume of Buffer RLT and 
perform steps 1.1 and 1.2 twice 
2. Transfer all cell lysate to QIA shredder spin column ❶ 
2.1. Centrifuge at 16.1x104 rcf for 2 minutes 
3. Add 600 ul of 70% ethanol to flow through from QIA 
shredder spin column 
3.1. Pipette up and down to mix 
4. Transfer 600 uL of flow through solutions to RNeasy spin 
column❷ 
4.1. Centrifuge at 16.1x104 rcf for 30 seconds 
4.2. Discard flow through in waste 
4.3. Repeat step 4 for the remaining flow through from 
QIA shredder spin column 
5. Add 700 uL RW 1 washing buffer to RNeasy spin column 
5.1. Centrifuge at 16.1x104 rcf for 30 seconds 
5.2. Discard flow through in waste 
6. Add 500 uL Buffer RPE to RNeasy spin column 
6.1. Centrifuge at 16.1x104 rcf for 30 seconds 
6.2. Discard flow through in waste 
7. Add 500 uL Buffer RPE to RNeasy spin column 
7.1. Let sit for 5 minutes 
7.2. Centrifuge at 16.1x104 rcf for 2 minutes 
7.3. Discard flow through in waste 
8. Centrifuge empty RNeasy spin column at 16.1x104 rcf for 
2 minutes 
9. Change gloves and wipe down with RNA zap wipes 
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10. Place RNeasy spin column in new, labeled 1.5 mL 
collection tube 
11. Add 30 uL RNase-free water to RNeasy spin column 
11.1. All the RNA is currently in the RNeasy spin column 
11.2. Centrifuge at 16.1x104 rcf for 1 minute 
11.3. SAVE FLOW THROUGH 
12. Repeat step 11 
13. Discard RNeasy spin column in biohazard 
13.1. RNA is in the flow through. DO NOT DISCARD 
FLOW THROUGH 
14. Store RNA at -80ᵒC 
E. Clean Up 
1. Discard remaining waste 
1.1. Spin columns, collection tubes, and pipette tips go in 
biohazard 
2. Return supplies and reagents to proper location 
3. Clean working area with 70% IPA 
F. Spectrophotometry – Nanodrop 2000 
In Bonderson: 
1. Open NanoDrop 2000 program on laptop 
2. Select Nucleic Acid 
3. Perform wavelength verification 
3.1. Remove Kim Wipe and lower arm 
4. Select RNA as sample type 
5. Rinse stage with RNAse-free water 
6. Blank spectrophotometer with RNAse-free water 
6.1. Add 1 uL RNAse-free water to the stage 
6.2. Lower arm and select “blank” 
7. Dry stage gently with kim wipe 
8. Name sample 
9. Add 1 uL of sample RNA to stage 
10. Lower arm and click “measure” 
10.1. Record concentration, 260/280, and 260/230 values 
10.2. Repeat measurement twice more 
10.3. Average three measurements 
11. Wipe down stage with RNAse-free water after each 
sample 
12. Leave Kim wipe under arm when finished 
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13. If the concentration of the RNA is high, it may be 
necessary to dilute the sample 
13.1. It is difficult to accurately pipette less than 1 uL 
values, so dilution will allow for greater pipetting accuracy 
13.2. Add small volumes of RNAse-free water to the RNA 
sample 
13.3. Test the concentration of the sample after each dilution 
until appropriate concentration is reached 
 
 
 
Revision History 
A Michael Gibbons 
Sarah Ur 
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APPENDIX G: PROTOCOL FOR CDNA SYNTHESIS 
Approx. Time:  
1.5 hours 
Procedure: 
A.  Preparation 
1. Using average concentration obtained in RNA assessment, 
calculate volume of RNA needed 
1.1. Determine amount of RNA (ng) for duration of experiment 
1.2. 200 ng to 1000 ng are needed to run qPCR 
1.2.1. We use 1000 ng 
1.3. (x ng of RNA)*(1 mL/[RNA ng/nL]) = Volume RNA (uL) 
2. Calculate amount of nuclease free water needed 
2.1. 15 uL – Volume RNA = Volume H2O (uL) 
3. Wipe down working area, micropipettes, and any other tools 
with RNAse Zap Wipes 
B.  iScript Transcription  
4. Prepare master mix 
4.1. 4 uL of 5X iScript Reaction Mix per sample 
4.2. 1 uL of RT per reaction 
4.3. Include additional 10% of each reagent for pipetting error 
4.4. Ex: for 3 samples, need 13.2 uL of 5X iScript + 1.1 uL RT 
Abbreviations: 
1. RT – reverse 
transcriptase 
Reminders: 
1. Keep working area 
and tools RNAse 
free 
2.Store iScript cDNA 
synthesis kit at -20ᵒC 
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Materials:  
1. iScript cDNA 
synthesis kit 
- 5x iScript 
Reaction mix 
- RT 
- RNAse free 
water 
2. Nuclease free tubes 
3. Thermal cycler tubes 
5. Label 1.5 mL/2mL nuclease free tubes for each sample 
6. Add 5 uL of master mix to each tube 
7. Add calculated volume of RNA and nuclease free water to each 
tube 
7.1. Centrifuge briefly 
8. Load samples (20 uL) into thermal cycler tubes and cap them. 
9. Place tubes into thermal cycler 
9.1. Ensure the lid of the thermal cycler is touching the caps of 
the tubes 
10. Run thermal cycler program “ISCRIPT” 
10.1. 25ᵒC for 5 minutes (300 seconds) 
10.2. 42ᵒC for 30 minutes (1800 seconds) 
10.3. 4ᵒC forever (hold) 
11. After cycling is completed, remove from thermal cycler 
12. Dilute cDNA 1:5 with 80 uL of nuclease free water 
13. Store cDNA at -20ᵒC 
 
Revision History 
A Michael Gibbons 
Sarah Ur 
120608 
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APPENDIX H: PROTOCOLS FOR CELL CULTURE FOR CONFOCAL 
MICROSCOPY 
Purpose: The purpose of this SOP is to guide the user in thawing into an 8-chamber slide for 
confocal microscopy 
Approx. Time:  
30 min 
Procedure: 
A. Preparation 
1. Assure lab hygiene protocol has been followed 
2.  “Open” the hood by raising the door to the marked line and turning 
on the light and pump 
3. Bring bottle of cell media into the hood  
4. Fill 8-chamber slides with cell media, 400 µL per well 
4.1. One vial could seed up to 25 8-chamber slides 
4.2. Determine how many are necessary 
4.3. Seed excess cells into an appropriate flask 
5. Fill flask with appropriate amount of media  
Flask Media 
T-25 9 ml 
T-75 20 ml 
5.1. 
6. Acquire Dewar Cell Notebook and find the desired cell type and 
location 
6.1. Location is based on canister -> cane -> position 
7. Take sticker out of the notebook and place it in your lab notebook 
 
B. Thawing 
1. Open Dewar 
2. Carefully take out the correct canister and cane  
3. Located the position of the desired cell vial on the rod 
4. Take the vial off, put cane into the Dewar, and close the Dewar 
Abbreviations: 
1. IPA – 
isopropyl 
alcohol 
Reminders: 
1. Always 
spray items 
with IPA 
before 
placing them 
in the hood. 
2. Be careful not to 
get water near the 
o-ring of the vial 
when thawing the 
cells. 
3. Avoid puncturing 
fragile glass 
bottom of 8-
chamber plates 
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Materials:  
18. 70% IPA 
19. 8-chamber 
slides 
20. Cell flask 
21. Cell Media 
22. Dewar 
Notebook 
23. Micropipette 
24. Micropipette 
tips 
25. Pipette 
26. 15 mL 
conical 
 
5. While holding the top of the vial, swirl the frozen vial in the water 
bath to thaw  
5.1.The vial may hiss and pop-- this is normal 
6. Once the vial is thawed, spray down with IPA 
7. Bring the thawed vial into the hood and loosen its cap 
8. Micropipette 5µL cell solution into 8-chamber slides  
9. Pipette additional cell solution into flask of media  
9.1. Ensure the whole cell solution is taken 
10. Place the slides and flask in the incubator  
 
C. Feeding 8-chamber slides 
11. Feed 8-chamber slides every 24 hours due to small size 
12. Bring the cell media into the laminar flow hood 
13. Bring 15ml conical(s) into hood 
14. Uncap bottle of cell media 
15. Pipette appropriate amount of media into conical(s)  
16. Recap conical(s) and place in warm water bath (37o C) 
17. Once media is warmed, bring back into hood. 
18. Bring 8-chamber slide out of incubator into the flow hood 
19. Acquire and additional conical and a P1000 micropipette and tips  
20. Remove lid from 8-chamber slide 
21. Aspirate cell media from all wells into a waste conical 
22. With fresh tips, dispense 400 µL cell media into each chamber 
23. Place slides into the incubator 
24. Aspirate liquid waste and dispose of trash 
25.  “Close” the hood by wiping down all surfaces with 70% IPA, 
turning off the pump and light, and pulling down the hood door to 
75% closed. 
 
 
Revision History: 
A Jakub Truty Summer 2013 
B Gabriella Sugerman 180708 
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APPENDIX I: PROTOCOLS FOR ROS PRODUCTION AND CELL VIABILITY 
ASSESSMENT  
Purpose: The purpose of this SOP is to guide the user in staining for ROS generation and 
viability assessment 
Approx. Time:  
3 hours 
Procedure: 
A. Make Staining Solutions 
1. Make 100 uM TBHP solution 
1.1 Add 1 μL TBHP to 77μL water to make 100mM stock  
1.2 Dilute stock 1:1000 in cell media  
2. Make 5 uM Carboxy-H2DCFDA solution 
2.1 Combine 50 uL DMSO with one vial powdered DCFDA and 
vortex to mix 
2.2 Combine 10 uL DCFDA with 4.0 mL HBSS 
3. Make 2 uM EthD solution 
3.1 Combine 5.1 uL 2 mM EthD stock in 844.9 uL HBSS 
4. Make 1 uM Hoechst solution 
4.1 Combine 10.8 uL Hoechst stock in 889.2 uL HBSS 
 
B. TBHP Positive Control Treatment 
1. Aspirate cell media from positive control samples 
2. Apply 200 uL of 100 uM TBHP solution for 60 minutes  
Abbreviations: 
4. ROS: 
Reactive 
Oxygen 
Species 
5. DMSO: 
dimethyl 
sulfoxide 
6. HBSS: Hank’s 
Buffered 
Saline 
Solution 
7. TBHP: known 
ROS inducer 
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Materials:  
Image-iT LIVE 
Green Reactive 
Oxygen Species 
Detection Kit 
(ThermoFisher) 
Carboxy-
H2DCFDA 
Hoechst 33342 
TBHP solution 
DMSO 
Ethidium 
Homodimer-1 
8-well plates 
 
 
C. Stain for ROS Generation and Viability 
41. Aspirate cell media or TBHP treatment from all wells 
42. Add 200 uL of 5uM DCFDA to each well for 20 minutes 
43. Add 50 uL each of Hoechst and EthD solutions to each well 
44. Remove all staining solutions and fill with warm HBSS for imaging 
D. Imaging  
1. Use the following filters for these stains:  
 
Dye Name Ex/Em (nm) Filter Used 
Hoechst 33342 350/461 DAPI 
Carboxy- 
H2DCFDA 
495/529 Alexa Fluor 488 
Ethidium Homodimer 528/617 Alexa Fluor 594 
 
 
Revision History: 
A Gabriella Sugerman 180708 
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APPENDIX J: PROTOCOLS FOR CONFOCAL IMAGING 
Purpose: The purpose of this SOP is to guide the user in the use of the confocal microscope. 
Approx. Time:  
Variable, ~1-5 hours 
depending on 
number of wells 
Procedure: 
A. Turning on the Confocal Microscope  
1. Sign up to use the confocal on the Google Calendar  
2. Sign into notebook (date; name; objective used; time in and lamp 
hours). 
3. Turn on boxes from left to right and bottom to top *after turning 
the key to ON for the last two boxes, wait five minutes before 
flipping the switch* – refer to ❶ {in progress} 
3.1. If not using widefield, don’t need to turn on top left box  
4. While waiting you can start the computer / Fluoview 
4.1. Computer login: Administrator, password: fluoview 
4.2. Fluoview does not have a password, just press enter 
4.3. Do not touch anything until after the program loads 
5. Explorer → open a previously saved load acquisition parameter 
 
B. Microscope Operation  
1. Buttons on focus knob 
1.1. (F/C) Fine/Course Focus Toggle- spinning the knob towards 
you will bring the objective up → can tell which one you’re using 
on “Microscope Controller” window 
1.2. (ESC) Escape objective – drop the objective down out of the 
way – use when you are changing samples 
2. Controller speeds: the button to the left of the joystick will change 
the speed – the default is the fastest speed, the button will toggle 
through three speeds 
3. Shutter: a filled circle means the shutter is “closed” and the light 
path is blocked; the circle outline is “open” 
Finding your sample 
1. Check sample and find general focus using widefield 
epifluorescence 
1.1. Click Translamp (top button) on “Image Acquisition Control” 
1.2. Click Mirror (U/B) on “Microscope Controller” to put the 
correct dichroic in place  
2. Switch to confocal using top left button “Image Acquisition 
Control”  
Reminders: 
1. Obtain 
permission from 
Dr. Cardinal 
and/or Dr. Lily 
Laiho before 
using the 
confocal 
microscope 
2. This is a VERY 
expensive piece 
of equipment—
always use care 
during operation. 
3. Promptly report 
all microscope 
issues to Dr. 
Laiho 
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 2.1. If you hear a clicking noise and the laser does not turn on, 
toggle between epifluorescence and XY Repeat until you see the 
laser  
3. After capturing images, save at least one as *.oib (this is the default 
save method) which will save all the information on your image 
acquisition settings so you know the HV, power, etc. 
3.1. To open *.oib files in ImageJ you will need the plugin 
Bioformats; Instead, after saving one image with the settings as 
*.oib, you can use the file, export as a multi-TIFF button – these 
images will open in ImageJ 
 
Various settings to alter image 
1. Scanning time on “Acquisition Setting” → scan as fast as you can 
with as low power as possible and still get a good image 
2. Laser power on “Acquisition Setting” → try to keep power at 20% 
or lower – if you need to dump more power in it could mean there 
is something wrong with your sample or you need a higher 
concentration - lower laser power if image is saturated 
3. HV – “High Voltage” on “Image Acquisition Control”→ keep 
around 700, HV changes the sensitivity; if your sample is dim you 
can up the HV and not have to up the power -  but can have more 
background noise 
4. Sequential box on “Image Acquisition Control” → when clicked 
the microscope will collect each pixel once with each laser channel 
– helps reduce effects of bleed-through  
 
Creating a z-stack 
1. Use focus knobs to bring focus to surface of sample (the area just 
black before you start to see an image), and set this as the start 
height in the z-stack window 
Materials:  
1. Confocal 
Microscope 
2. Sample on glass 
slide or 
chamberglass 
system 
3. Immersion oil 
Methanol 
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 2. Use focus knobs to scan through sample until you reach the ‘end’ 
(the end point of when your image starts to disappear) and set this 
as the end height 
3. Click Stop, then click the XY Z button just to the left of the Stop 
button 
4. The step size or number of slices can be altered to change how 
many slices – a larger number of slices will take longer to image 
 
C. Turning off the Confocal Microscope  
1. Clean all objectives used with Methanol and lens paper 
2. If someone is scheduled to use the confocal within 1-2 hours of 
you, check with them to verify they will be coming and leave the 
microscope on 
3. To turn off the confocal, turn the keys for the last two boxes OFF 
then WAIT 5 MINUTES before flipping the switches 
4. Turn off the boxes from right to left and top to bottom, the opposite 
as they were turned on  
5. Close both shutters 
6. Turn off the computer 
7. Sign out of the notebook (time out and lamp hours). 
 
 
Revision History 
A Julia Thulin Summer 2018 
B Gabriella Sugerman 180708 
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APPENDIX K: MACROS FOR IMAGE PROCESSING  
Note: change "[YOUR FOLDER’S LOCATION]" to the path to where you want images saved, 
for example “C:/Desktop/My Images”  
function split(inputDir, filename) { 
 open(inputDir + filename); 
 run("Split Channels"); 
 selectWindow("C1-" + filename); 
 saveAs("Tiff", "[YOUR FOLDER’S LOCATION]/C1-" + filename); 
 selectWindow("C2-" + filename); 
 saveAs("Tiff", ""[YOUR FOLDER’S LOCATION]/C2-" + filename); 
 selectWindow("C3-" + filename); 
 saveAs("Tiff", "[YOUR FOLDER’S LOCATION]/C3-" + filename); 
 close(); 
} 
setBatchMode(true); 
inputDir = getDirectory("Choose input directory"); 
fileList = getFileList(inputDir); 
for (i = 0; i < fileList.length; i++) { 
 showProgress(i, fileList.length); 
 split(inputDir, fileList[i]); 
} 
resultsDir = “[YOUR FOLDER’S LOCATION]” ; 
 
function meangray(zProjectDir, maskDir, zProjectFile, maskFile) { 
 open(maskDir + maskFile); 
 selectWindow(maskFile); 
 run("Analyze Particles...", "size=10-Infinity add"); 
 open(zProjectDir + zProjectFile); 
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 selectWindow(zProjectFile); 
 roiManager("Select", Array.getSequence(roiManager("count"))); 
 roiManager("Measure"); 
 saveAs("Results", resultsDir + maskFile + "Results.csv"); 
 Table.deleteRows(0, Table.size); 
} 
 
setBatchMode(true); 
zProjectDir = getDirectory("Z Projections input directory"); 
maskDir = getDirectory("Masks input directory"); 
zFileList = getFileList(zProjectDir); 
maskFileList = getFileList(maskDir); 
for (i = 0; i < zFileList.length; i++) { 
 meangray(zProjectDir, maskDir, zFileList[i], maskFileList[i]); 
} 
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APPENDIX L: ANOVA REPORTS 
 
qPCR  
IL-6 Day 7 
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IL-6 Day 14  
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Imaging  
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APPENDIX M: RAW DATA 
qPCR  
Testing Custom Primers  
Well Sample Name Ct 
E4 ACTB 30.1907 
F4 ACTB 32.1067 
G4 ACTB 30.1604 
H4 ACTB Undetermined 
A4 CD36-1 Undetermined 
B4 CD36-1 Undetermined 
C4 CD36-1 Undetermined 
D4 CD36-1 Undetermined 
A3 CD36-2 Undetermined 
B3 CD36-2 Undetermined 
C3 CD36-2 Undetermined 
D3 CD36-2 13.6893 
A5 CD68-1 31.9268 
B5 CD68-1 30.7794 
C5 CD68-1 30.4113 
D5 CD68-1 Undetermined 
A6 CD68-9 Undetermined 
B6 CD68-9 Undetermined 
C6 CD68-9 Undetermined 
D6 CD68-9 Undetermined 
E3 GAPDH 21.3126 
F3 GAPDH 20.5271 
G3 GAPDH 20.2041 
H3 GAPDH Undetermined 
A7 IL1A-1 Undetermined 
B7 IL1A-1 Undetermined 
C7 IL1A-1 Undetermined 
D7 IL1A-1 Undetermined 
A8 IL1A-6 36.894 
B8 IL1A-6 35.4699 
C8 IL1A-6 35.2767 
D8 IL1A-6 Undetermined 
A1 IL6-2 Undetermined 
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B1 IL6-2 Undetermined 
C1 IL6-2 Undetermined 
D1 IL6-2 Undetermined 
A2 IL6-8 Undetermined 
B2 IL6-8 Undetermined 
C2 IL6-8 29.1564 
D2 IL6-8 Undetermined 
A9 PLA2G7-1 Undetermined 
B9 PLA2G7-1 Undetermined 
C9 PLA2G7-1 39.4996 
D9 PLA2G7-1 Undetermined 
A10 PLA2G7-4 Undetermined 
B10 PLA2G7-4 Undetermined 
C10 PLA2G7-4 Undetermined 
D10 PLA2G7-4 Undetermined 
A12 PPARG-1 38.5619 
B12 PPARG-1 39.2674 
C12 PPARG-1 38.5588 
D12 PPARG-1 Undetermined 
A11 PPARG-6 Undetermined 
B11 PPARG-6 Undetermined 
C11 PPARG-6 37.2391 
D11 PPARG-6 Undetermined 
E2 PTGS2-1 27.7264 
F2 PTGS2-1 29.0332 
G2 PTGS2-1 27.5553 
H2 PTGS2-1 Undetermined 
E1 PTGS2-5 31.7588 
F1 PTGS2-5 32.4068 
G1 PTGS2-5 32.2364 
H1 PTGS2-5 Undetermined 
 
Standard Curves 
Dilution Sample Name Ct 
0 B2M NTC 
0 CD36 NTC 
0 HPRT1 NTC 
0 IL6 NTC 
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0.125 B2M 23.0772 
0.125 B2M 27.6819 
0.125 B2M 26.4787 
0.125 CD36 36.1385 
0.125 CD36 36.6827 
0.125 CD36 36.6919 
0.125 HPRT1 29.2113 
0.125 HPRT1 29.6163 
0.125 IL6 38.1149 
0.125 IL6 36.5813 
0.125 IL6 37.1748 
0.25 B2M 21.5211 
0.25 B2M 21.1977 
0.25 B2M 18.4869 
0.25 CD36 29.6911 
0.25 CD36 29.0239 
0.25 CD36 28.3647 
0.25 HPRT1 25.2433 
0.25 HPRT1 24.5271 
0.25 HPRT1 23.48 
0.25 IL6 28.745 
0.25 IL6 28.1088 
0.25 IL6 30.802 
0.5 B2M 17.7577 
0.5 B2M 20.5211 
0.5 B2M 20.0036 
0.5 CD36 27.8352 
0.5 CD36 27.9685 
0.5 HPRT1 25.0905 
0.5 HPRT1 24.2611 
0.5 HPRT1 24.4024 
0.5 IL6 29.0582 
0.5 IL6 27.2563 
0.5 IL6 25.5381 
0.66 B2M 19.3963 
0.66 B2M 19.0834 
0.66 B2M 19.3424 
0.66 CD36 26.8425 
0.66 CD36 26.7447 
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0.66 CD36 27.7586 
0.66 HPRT1 23.0095 
0.66 HPRT1 22.9605 
0.66 HPRT1 25.6776 
0.66 IL6 26.9784 
0.66 IL6 27.9516 
0.66 IL6 28.0519 
1 B2M 18.6161 
1 B2M 18.66 
1 B2M 18.2691 
1 CD36 25.5029 
1 CD36 25.7805 
1 CD36 25.352 
1 HPRT1 21.7249 
1 HPRT1 22.0442 
1 HPRT1 21.8862 
1 IL6 26.6202 
1 IL6 27.0045 
1 IL6 26.8122 
 
B2M 
 
y = -7.4058x + 17.73
R² = 0.8264
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CD36 
HPRT1 
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IL-6 
 
7-Day 
Well Treatment Gene Ct 
C7 HI B2M 16.5737 
C8 HI B2M 15.4438 
C9 HI B2M 16.5884 
C10 HI B2M 18.1863 
C11 HI B2M 16.8739 
C12 HI B2M 16.7503 
A10 LO B2M 17.039 
A11 LO B2M 15.8062 
A12 LO B2M 17.3592 
C1 LO B2M 27.5071 
C2 LO B2M 27.2663 
C3 LO B2M 22.8186 
B10 MED B2M 29.5639 
B11 MED B2M 30.457 
B12 MED B2M 30.9849 
C4 MED B2M 29.8669 
C5 MED B2M 29.4111 
C6 MED B2M 30.1312 
C7 HI CD36 32.3459 
C8 HI CD36 31.413 
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C9 HI CD36 32.3175 
D7 HI CD36 32.7263 
D8 HI CD36 33.8288 
D9 HI CD36 32.8417 
E7 HI CD36 34.3413 
E8 HI CD36 34.3691 
E9 HI CD36 34.096 
C1 LO CD36 29.5586 
C2 LO CD36 30.0567 
C11 LO CD36 32.2382 
D1 LO CD36 33.5947 
D2 LO CD36 33.931 
D3 LO CD36 34.1809 
E1 LO CD36 33.7902 
E2 LO CD36 34.321 
E3 LO CD36 34.3671 
C4 MED CD36 30.2788 
C5 MED CD36 31.9086 
C6 MED CD36 32.0858 
D4 MED CD36 36.0872 
D5 MED CD36 34.41 
D6 MED CD36 35.0283 
E4 MED CD36 37.4925 
E5 MED CD36 35.3379 
E6 MED CD36 35.4833 
D7 HI HPRT1 25.2667 
D8 HI HPRT1 25.7063 
D9 HI HPRT1 24.3609 
F7 HI HPRT1 23.7603 
F8 HI HPRT1 23.6228 
F9 HI HPRT1 24.5639 
F10 HI HPRT1 23.016 
F11 HI HPRT1 22.8775 
F12 HI HPRT1 23.0758 
D1 LO HPRT1 26.3175 
D2 LO HPRT1 26.5942 
D3 LO HPRT1 26.0351 
D10 LO HPRT1 21.8116 
D11 LO HPRT1 21.6623 
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D12 LO HPRT1 21.9446 
F1 LO HPRT1 23.9188 
F2 LO HPRT1 24.032 
F3 LO HPRT1 23.9561 
D4 MED HPRT1 24.7127 
D5 MED HPRT1 26.419 
D6 MED HPRT1 29.6952 
E10 MED HPRT1 34.5903 
E11 MED HPRT1 34.2394 
E12 MED HPRT1 37.4171 
F4 MED HPRT1 37.9427 
F5 MED HPRT1 33.974 
F6 MED HPRT1 35.8646 
E7 HI IL6 28.3562 
E8 HI IL6 29.5847 
E9 HI IL6 28.4396 
G7 HI IL6 24.543 
G8 HI IL6 25.2714 
G9 HI IL6 25.7953 
H7 HI IL6 25.7429 
H8 HI IL6 25.9784 
H9 HI IL6 23.0983 
E1 LO IL6 30.9258 
E2 LO IL6 32.3991 
E3 LO IL6 33.1362 
G1 LO IL6 29.8728 
G2 LO IL6 30.2608 
G3 LO IL6 30.0085 
H1 LO IL6 30.1801 
H2 LO IL6 29.6681 
H3 LO IL6 29.5398 
E4 MED IL6 32.808 
E5 MED IL6 27.8487 
G4 MED IL6 37.2573 
G5 MED IL6 37.1969 
G6 MED IL6 38.2392 
H4 MED IL6 39.3774 
H5 MED IL6 36.6946 
H6 MED IL6 39.4759 
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14-Day 
Well 
Sample 
Name   
C7 B2M High 16.501 
C8 B2M High 15.3167 
C9 B2M High 16.2626 
C10 B2M High 18.2288 
C11 B2M High 16.5286 
C12 B2M High 16.5769 
A10 B2M Low 17.2563 
A11 B2M Low 15.6395 
A12 B2M Low 17.5486 
C1 B2M Low 27.8592 
C2 B2M Low 27.8396 
C3 B2M Low 22.143 
B10 B2M Med 29.7833 
B11 B2M Med 30.239 
B12 B2M Med 30.4743 
C4 B2M Med 29.7935 
C5 B2M Med 29.5778 
C6 B2M Med 30.0428 
D7 CD36 High 32.0553 
D8 CD36 High 33.6727 
D9 CD36 High 32.2795 
E7 CD36 High 34.1963 
E8 CD36 High 34.844 
E9 CD36 High 34.6044 
D1 CD36 Low 33.3387 
D2 CD36 Low 33.7992 
D3 CD36 Low 34.7206 
E1 CD36 Low 33.4278 
E2 CD36 Low 34.1016 
E3 CD36 Low 34.3213 
D4 CD36 Med 36.2395 
D5 CD36 Med 34.8253 
D6 CD36 Med 35.7204 
E4 CD36 Med 37.3185 
E5 CD36 Med 35.2208 
E6 CD36 Med 35.6133 
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F7 HPRT1 High 23.9428 
F8 HPRT1 High 23.9193 
F9 HPRT1 High 24.9483 
F10 HPRT1 High 23.5463 
F11 HPRT1 High 22.8958 
F12 HPRT1 High 23.3137 
D10 HPRT1 Low 21.0103 
D11 HPRT1 Low 21.9891 
D12 HPRT1 Low 21.7481 
F1 HPRT1 Low 23.0031 
F2 HPRT1 Low 24.6064 
F3 HPRT1 Low 23.0133 
E10 HPRT1 Med 34.0225 
E11 HPRT1 Med 34.0841 
E12 HPRT1 Med 37.8044 
F4 HPRT1 Med 37.7632 
F5 HPRT1 Med 33.3542 
F6 HPRT1 Med 35.6349 
G7 IL6 High 24.1783 
G8 IL6 High 25.6371 
G9 IL6 High 25.9949 
H7 IL6 High 25.2269 
H8 IL6 High 25.8689 
H9 IL6 High 23.4803 
G1 IL6 Low 29.0572 
G2 IL6 Low 30.4029 
G3 IL6 Low 30.3321 
H1 IL6 Low 30.8583 
H2 IL6 Low 29.5542 
H3 IL6 Low 29.5898 
G4 IL6 Med 37.47 
G5 IL6 Med 37.7869 
G6 IL6 Med 38.6494 
H4 IL6 Med 39.7318 
H5 IL6 Med 36.4187 
H6 IL6 Med 39.5854 
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Probe-Quencher Reporting 
Well Sample Name Detector Ct 
A1 ACTB Basal FAM/IowaBlack 32.5204 
A2 ACTB Basal FAM/IowaBlack 30.1749 
B1 ACTB Basal FAM/IowaBlack 34.6902 
B2 ACTB Basal FAM/IowaBlack 25.2126 
B3 ACTB Basal FAM/IowaBlack 33.6815 
A8 ACTB High FAM/IowaBlack 21.3877 
B7 ACTB High FAM/IowaBlack 15.6414 
B8 ACTB High FAM/IowaBlack 39.3752 
A4 ACTB Med FAM/IowaBlack 3.60218 
B6 ACTB Med FAM/IowaBlack 3.9693 
C1 B2M Basal FAM/IowaBlack 20.6675 
C2 B2M Basal FAM/IowaBlack 22.2837 
C3 B2M Basal FAM/IowaBlack 37.5111 
D1 B2M Basal FAM/IowaBlack 21.2299 
D2 B2M Basal FAM/IowaBlack 25.4048 
C9 B2M High FAM/IowaBlack 17.0982 
D8 B2M High FAM/IowaBlack 25.5236 
D9 B2M High FAM/IowaBlack 32.9716 
C5 B2M Med FAM/IowaBlack 19.0237 
D5 B2M Med FAM/IowaBlack 32.7524 
C11 CD36 High FAM/IowaBlack 26.0339 
E7 CD36 High FAM/IowaBlack 35 
E9 CD36 High FAM/IowaBlack 21.201 
B10 CD36 Med FAM/IowaBlack 17.6432 
E5 CD36 Med FAM/IowaBlack 17.0716 
E6 CD36 Med FAM/IowaBlack 34.2663 
H10 HPRT1 Basal FAM/IowaBlack 38.2972 
D10 HPRT1 Basal FAM/IowaBlack 29.0237 
D12 HPRT1 Basal FAM/IowaBlack 29.8932 
F2 HPRT1 Basal FAM/IowaBlack 31.091 
F7 HPRT1 High FAM/IowaBlack 29.156 
F9 HPRT1 High FAM/IowaBlack 20.2456 
F11 HPRT1 High FAM/IowaBlack 24.0113 
F12 HPRT1 High FAM/IowaBlack 29.3666 
E10 HPRT1 Med FAM/IowaBlack 20.8872 
E12 HPRT1 Med FAM/IowaBlack 31.5817 
F4 HPRT1 Med FAM/IowaBlack 26.6884 
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G1 IL6 Basal FAM/IowaBlack 37.4332 
G3 IL6 Basal FAM/IowaBlack 7.89384 
H1 IL6 Basal FAM/IowaBlack 31.937 
H3 IL6 Basal FAM/IowaBlack 33.6775 
G7 IL6 High FAM/IowaBlack 35.3243 
G9 IL6 High FAM/IowaBlack 28.6016 
H8 IL6 High FAM/IowaBlack 28.953 
G4 IL6 Med FAM/IowaBlack 20.127 
H4 IL6 Med FAM/IowaBlack 27.9408 
H5 IL6 Med FAM/IowaBlack 26.0028 
H6 IL6 Med FAM/IowaBlack 26.1645 
 
Image Analysis 
Experiment 1 
    Count Hoechst Count EthD Count ROS MGV ROS 
48 hour Basal 6 8 0 1911.49 
48 hour Basal 9 1 6 1407.98 
48 hour Basal 9 8 3 2203.85 
24 hour Moderate 49 17 21 1949.77 
48 hour Moderate 12 13 1 1996.06 
24 hour High 10 9 2 3575.85 
24 hour High 31 8 9 2004.7 
48 hour High 10 11 1 2230.1 
24 hour Basal 34 34 1 1774.19 
24 hour Moderate 24 28 9 1783.68 
24 hour High 42 51 31 1979.34 
48 hour Basal 3 1 2 1343.84 
48 hour Basal 151 10 143 2315.86 
48 hour Moderate 15 19 5 1862.65 
48 hour Moderate 4 8 1 1867.15 
48 hour High 20 2 22 1805.47 
48 hour High 20 25 11 1868.65 
24 hour Basal 6 43 11 1864.96 
24 hour Moderate 21 90 26 2003.24 
24 hour High 68 101 66 2618.73 
48 hour Basal 13 13 11 2080.44 
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48 hour Basal 17 14 15 2106.7 
48 hour Moderate 19 15 2 2161.07 
48 hour Moderate 32 13 4 2157.66 
48 hour High 14 6 15 1882.39 
48 hour High 8 11 2 1907.97 
 
Experiment 2 Day 1 Raw 
Stain Treatment Particle Count Area Mean Gray Value 
Hoechst Basal 103 31343.4 304.3052 
Hoechst Basal 66 13219.8 200.3001 
Hoechst Basal 94 20415.9 217.1903 
Hoechst Basal 178 65772 369.5056 
ROS Basal 7 8781.84 1254.5484 
ROS Basal 9 3185.4 353.9336 
ROS Basal 17 7462.94 438.9966 
ROS Basal 61 29785.4 488.2859 
EthD Basal 7 1072.08 153.1549 
EthD Basal 2 410.323 205.1615 
EthD Basal 7 1389.85 198.5505 
EthD Basal 30 4314.56 143.8187 
Hoechst Moderate 98 17967.8 183.3452 
Hoechst Moderate 113 24239.9 214.5125 
Hoechst Moderate 76 15544.5 204.5323 
Hoechst Moderate 115 23434.7 203.7799 
ROS Moderate 40 10967.7 274.1914 
ROS Moderate 30 14865.7 495.5242 
ROS Moderate 7 1318.9 188.4136 
ROS Moderate 6 1366.72 227.7858 
EthD Moderate 6 928.626 154.771 
EthD Moderate 5 811.391 162.2781 
EthD Moderate 4 735.805 183.9512 
EthD Moderate 6 854.583 142.4304 
Hoechst High 8 1611.98 201.4979 
Hoechst High 19 3083.59 162.2944 
Hoechst High 10 1610.44 161.0441 
Hoechst High 88 17653.1 200.6039 
ROS High 2 439.632 219.8159 
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ROS High 11 2730.34 248.2132 
ROS High 51 18736 367.3731 
ROS High 19 6273.62 330.1907 
EthD High 0 0 NaN 
EthD High 11 1679.86 152.7142 
EthD High 1 112.607 112.6074 
EthD High 8 1260.28 157.5347 
Experiment 2 Day 2 Raw 
Treatment Stain Particle Count Mean Gray Value 
Positive Control Hoechst 126 5469.95 
Positive Control Hoechst 4 111.065 
Positive Control Hoechst 185 5724.47 
Positive Control Hoechst 96 4965.53 
Basal Hoechst 84 2204.33 
Basal Hoechst 12 370.216 
Basal Hoechst 154 14387.5 
Basal Hoechst 480 66791.6 
Moderate  Hoechst 12 183.566 
Moderate  Hoechst 30 1470.07 
Moderate  Hoechst 662 63249.9 
Moderate  Hoechst 16 504.42 
High Hoechst 201 19001.3 
High Hoechst 645 33191.4 
High Hoechst 102 10671.5 
High Hoechst 239 22132.8 
Positive Control EthD 154 4988.66 
Positive Control EthD 8 175.853 
Positive Control EthD 335 9346.42 
Positive Control EthD 40 1004.21 
Basal EthD 95 2869.18 
Basal EthD 25 965.647 
Basal EthD 27 939.424 
Basal EthD 104 3154.55 
Moderate  EthD 15 504.42 
Moderate  EthD 29 933.254 
Moderate  EthD 169 5161.43 
Moderate  EthD 19 968.733 
High EthD 109 2987.95 
  
 
145 
 
High EthD 330 9526.9 
High EthD 55 1806.35 
High EthD 77 2429.54 
Positive Control ROS 25 13696.5 
Positive Control ROS 24 21140.9 
Positive Control ROS 4 447.345 
Basal ROS 7 8781.84 
Basal ROS 9 3185.4 
Basal ROS 17 7462.94 
Basal ROS 61 29785.4 
Moderate  ROS 40 10967.7 
Moderate  ROS 30 14865.7 
Moderate  ROS 7 1318.9 
Moderate  ROS 6 1366.72 
High ROS 2 439.632 
High ROS 11 2730.34 
High ROS 51 18736 
High ROS 19 6273.62 
 
